
1: Mease PJ, Gladman DD, Helliwell P, Khraishi MM, Fuiman J, Bananis E, Alvarez
D. Comparative performance of psoriatic arthritis screening tools in patients
with psoriasis in European/North American dermatology clinics. J Am Acad
Dermatol. 2014 Oct;71(4):649-55. doi: 10.1016/j.jaad.2014.05.010. Epub 2014 Jun
25. PubMed PMID: 24974240.


2: Boggs RL, Kárpáti S, Li W, Williams T, Pedersen R, Mallbris L, Gniadecki R.
Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis
patients with etanercept treatment. BMC Dermatol. 2014 Aug 5;14:14. doi:
10.1186/1471-5945-14-14. PubMed PMID: 25091090; PubMed Central PMCID: PMC4147874.


3: López Estebaránz JL, Zarco-Montejo P, Samaniego ML, García-Calvo C; PREVAL
Study Group. Prevalence and clinical features of psoriatic arthritis in psoriasis
patients in Spain. Limitations of PASE as a screening tool. Eur J Dermatol. 2015 
Jan-Feb;25(1):57-63. doi: 10.1684/ejd.2014.2449. PubMed PMID: 25333645.


4: Puig L, Strohal R, Husni ME, Tsai TF, Noppakun N, Szumski A, Yang S, Robertson
D, Boggs R, Koenig AS. Cardiometabolic profile, clinical features, quality of
life and treatment outcomes in patients with moderate-to-severe psoriasis and
psoriatic arthritis. J Dermatolog Treat. 2015 Feb;26(1):7-15. doi:
10.3109/09546634.2013.860209. Epub 2013 Nov 27. PubMed PMID: 24283931.


5: Duman N, Ersoy-Evans S, Karadağ O, Aşçıoğlu S, Sener B, Kiraz S, Sahin S.
Screening for latent tuberculosis infection in psoriasis and psoriatic arthritis 
patients in a tuberculosis-endemic country: a comparison of the QuantiFERON®-TB
Gold In-Tube test and tuberculin skin test. Int J Dermatol. 2014
Oct;53(10):1286-92. doi: 10.1111/ijd.12522. Epub 2014 Jul 11. PubMed PMID:
25039468.


6: Naegeli AN, Flood E, Tucker J, Devlen J, Edson-Heredia E. The Worst Itch
Numeric Rating Scale for patients with moderate to severe plaque psoriasis or
psoriatic arthritis. Int J Dermatol. 2015 Jun;54(6):715-22. doi:
10.1111/ijd.12645. Epub 2014 Dec 16. PubMed PMID: 25515935.


7: Papp K, Menter A, Strober B, Kricorian G, Thompson EH, Milmont CE, Nirula A,
Klekotka P. Efficacy and safety of brodalumab in subpopulations of patients with 
difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2015 
Mar;72(3):436-439.e1. doi: 10.1016/j.jaad.2014.10.026. Epub 2014 Dec 29. PubMed
PMID: 25553889.


8: Hayashi M, Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Efficacy and
safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol.
2014 Nov;41(11):974-80. doi: 10.1111/1346-8138.12653. PubMed PMID: 25346301.


9: Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, Goyal K,
Fakharzadeh S, Calabro S, Chevrier M, Langholff W, You Y, Leonardi CL. Risk of
Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From
the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015 
Sep;151(9):961-9. doi: 10.1001/jamadermatol.2015.0718. PubMed PMID: 25970800.


10: Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaçi D. Influence
of psoriatic arthritis on the efficacy of adalimumab and on the treatment
response of other markers of psoriasis burden: subanalysis of the BELIEVE study. 
Eur J Dermatol. 2012 Nov-Dec;22(6):762-9. doi: 10.1684/ejd.2012.1863. PubMed
PMID: 23178916.


11: Piaserico S, Sandini E, Saldan A, Abate D. Effects of TNF-alpha inhibitors on
circulating Th17 cells in patients affected by severe psoriasis. Drug Dev Res.
2014 Nov;75 Suppl 1:S73-6. doi: 10.1002/ddr.21202. PubMed PMID: 25381985.


12: Nardis C, Anzivino E, Bellizzi A, Rodio DM, De Pità O, Chiarini F,
Pietropaolo V. Reactivation of human polyomavirus JC in patients affected by
psoriasis vulgaris and psoriatic arthritis and treated with biological drugs:
preliminary results. J Cell Physiol. 2012 Dec;227(12):3796-802. doi:
10.1002/jcp.24089. PubMed PMID: 22422468.


13: Griffiths CE, Sterry W, Brock F, Dilleen M, Stefanidis D, Germain JM,
Mallbris L. Pattern of response in patients with moderate-to-severe psoriasis
treated with etanercept. Br J Dermatol. 2015 Jan;172(1):230-8. doi:
10.1111/bjd.13139. Epub 2014 Nov 13. PubMed PMID: 24861696.


14: Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, 
Zbrozek AS. Self-reported health outcomes in patients with psoriasis and
psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol
Venereol. 2012 Nov;26(11):1436-43. doi: 10.1111/j.1468-3083.2011.04308.x. Epub
2011 Oct 31. PubMed PMID: 22035157.


15: Strober BE, Poulin Y, Teller C, Wang Y, Williams DA, Goldblum OM. Changes in 
C-reactive protein in patients with moderate-to-severe psoriasis switched to
adalimumab therapy after suboptimal response to etanercept, methotrexate or
phototherapy. J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1701-6. doi:
10.1111/jdv.12372. Epub 2014 Jan 15. PubMed PMID: 24422992.


16: Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, Zack DJ, Fiorentino D.
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic
arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012 
Jul;71(7):1143-50. doi: 10.1136/annrheumdis-2011-200387. Epub 2012 Jan 17. PubMed
PMID: 22258482; PubMed Central PMCID: PMC3375587.


17: Tinazzi I, Adami S, Zanolin EM, Caimmi C, Confente S, Girolomoni G, Gisondi
P, Biasi D, McGonagle D. The early psoriatic arthritis screening questionnaire: a
simple and fast method for the identification of arthritis in patients with
psoriasis. Rheumatology (Oxford). 2012 Nov;51(11):2058-63. doi:
10.1093/rheumatology/kes187. Epub 2012 Aug 9. PubMed PMID: 22879464.


18: Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y,
Valdes JM, Mulani PM. Effects of briakinumab treatment for moderate to severe
psoriasis on health-related quality of life and work productivity and activity
impairment: results from a randomized phase III study. J Eur Acad Dermatol
Venereol. 2014 Jun;28(6):790-8. doi: 10.1111/jdv.12177. Epub 2013 May 17. PubMed 
PMID: 23679896.


19: Demirel R, Genc A, Ucok K, Kacar SD, Ozuguz P, Toktas M, Sener U, Karabacak
H, Karaca S. Do patients with mild to moderate psoriasis really have a sedentary 
lifestyle? Int J Dermatol. 2013 Sep;52(9):1129-34. doi: 10.1111/ijd.12042. Epub
2013 Jul 24. PubMed PMID: 23879519.


20: Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD,
Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G.
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled
trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014
Jun;73(6):1020-6. doi: 10.1136/annrheumdis-2013-205056. Epub 2014 Mar 4. PubMed
PMID: 24595547; PubMed Central PMCID: PMC4033106.


21: Kirkham B, de Vlam K, Li W, Boggs R, Mallbris L, Nab HW, Tarallo M. Early
treatment of psoriatic arthritis is associated with improved patient-reported
outcomes: findings from the etanercept PRESTA trial. Clin Exp Rheumatol. 2015
Jan-Feb;33(1):11-9. Epub 2014 Dec 22. PubMed PMID: 25535650.


22: Zhu X, Zheng M, Song M, Shen YK, Chan D, Szapary PO, Wang B; LOTUS
Investigators. Efficacy and safety of ustekinumab in Chinese patients with
moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial
(LOTUS). J Drugs Dermatol. 2013 Feb;12(2):166-74. PubMed PMID: 23377389.


23: Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C,
Draelos Z, Gold MH; Psoriasis Study Group, Durez P, Tak PP, Gomez-Reino JJ;
Rheumatoid Arthritis Study Group, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, 
Callanan D, Nguyen QD; Uveitis Study Group, Rose K, Haider A, Di Padova F.
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis,
rheumatoid arthritis, and uveitis. Sci Transl Med. 2010 Oct 6;2(52):52ra72. doi: 
10.1126/scitranslmed.3001107. PubMed PMID: 20926833.


24: Prinz JC, Fitzgerald O, Boggs RI, Foehl J, Robertson D, Pedersen R, Molta CT,
Freundlich B. Combination of skin, joint and quality of life outcomes with
etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. J Eur Acad
Dermatol Venereol. 2011 May;25(5):559-64. doi: 10.1111/j.1468-3083.2010.03838.x. 
Epub 2010 Sep 14. PubMed PMID: 20840349.


25: Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK,
Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group. Efficacy and safety 
of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with
active psoriatic arthritis despite conventional non-biological and biological
anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3,
multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann
Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 
Jan 30. PubMed PMID: 24482301; PubMed Central PMCID: PMC4033144.


26: Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun
MM, Mulani PM. Sleep quality and other patient-reported outcomes improve after
patients with psoriasis with suboptimal response to other systemic therapies are 
switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Br
J Dermatol. 2012 Dec;167(6):1374-81. doi: 10.1111/bjd.12000. Epub 2012 Nov 2.
PubMed PMID: 22897348.


27: Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O'Dwyer JL,
Meads DM, Emery P, Conaghan PG, Helliwell PS. Effect of tight control of
inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label,
randomised controlled trial. Lancet. 2015 Dec 19;386(10012):2489-98. doi:
10.1016/S0140-6736(15)00347-5. Epub 2015 Oct 1. PubMed PMID: 26433318.


28: Hull DN, Williams RO, Pathan E, Alzabin S, Abraham S, Taylor PC. Anti-tumour 
necrosis factor treatment increases circulating T helper type 17 cells similarly 
in different types of inflammatory arthritis. Clin Exp Immunol. 2015
Sep;181(3):401-6. doi: 10.1111/cei.12626. Epub 2015 Jun 23. PubMed PMID:
25766640; PubMed Central PMCID: PMC4557375.


29: Nanus DE, Filer AD, Hughes B, Fisher BA, Taylor PC, Stewart PM, Buckley CD,
McInnes I, Cooper MS, Raza K. TNFα regulates cortisol metabolism in vivo in
patients with inflammatory arthritis. Ann Rheum Dis. 2015 Feb;74(2):464-9. doi:
10.1136/annrheumdis-2013-203926. Epub 2014 Jan 2. PubMed PMID: 24385202.


30: Lebre MC, Jonckheere CL, Kraan MC, van Kuijk AW, Bos JD, de Rie M, Gerlag DM,
Tak PP. Expression of IL-20 in synovium and lesional skin of patients with
psoriatic arthritis: differential response to alefacept treatment. Arthritis Res 
Ther. 2012 Sep 24;14(5):R200. doi: 10.1186/ar4038. PubMed PMID: 23006144; PubMed 
Central PMCID: PMC3580512.


31: Cozzi F, Raffeiner B, Beltrame V, Ciprian L, Coran A, Botsios C, Perissinotto
E, Grisan E, Ramonda R, Oliviero F, Stramare R, Punzi L. Effects of mud-bath
therapy in psoriatic arthritis patients treated with TNF inhibitors. Clinical
evaluation and assessment of synovial inflammation by contrast-enhanced
ultrasound (CEUS). Joint Bone Spine. 2015 Mar;82(2):104-8. doi:
10.1016/j.jbspin.2014.11.002. Epub 2015 Jan 23. PubMed PMID: 25623520.


32: Scrivo R, Conigliaro P, Riccieri V, Di Franco M, Alessandri C, Spadaro A,
Perricone R, Valesini G. Distribution of interleukin-10 family cytokines in serum
and synovial fluid of patients with inflammatory arthritis reveals different
contribution to systemic and joint inflammation. Clin Exp Immunol. 2015
Feb;179(2):300-8. doi: 10.1111/cei.12449. PubMed PMID: 25178435; PubMed Central
PMCID: PMC4298407.


33: Torii H, Nakagawa H; Japanese Infliximab Study investigators. Infliximab
monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and
psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter
trial. J Dermatol Sci. 2010 Jul;59(1):40-9. doi: 10.1016/j.jdermsci.2010.04.014. 
Epub 2010 May 4. PubMed PMID: 20547039.


34: Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D,
Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D. Effect of
certolizumab pegol on signs and symptoms in patients with psoriatic arthritis:
24-week results of a Phase 3 double-blind randomised placebo-controlled study
(RAPID-PsA). Ann Rheum Dis. 2014 Jan;73(1):48-55. doi:
10.1136/annrheumdis-2013-203696. Epub 2013 Aug 13. PubMed PMID: 23942868; PubMed 
Central PMCID: PMC3888622.


35: Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D,
Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A. Clinical efficacy, radiographic and
safety findings through 5 years of subcutaneous golimumab treatment in patients
with active psoriatic arthritis: results from a long-term extension of a
randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014
Sep;73(9):1689-94. doi: 10.1136/annrheumdis-2013-204902. Epub 2014 Apr 19. PubMed
PMID: 24748630; PubMed Central PMCID: PMC4145441.


36: Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan 
L, Brodmerkel C, Song M, Mendelsohn AM, McInnes IB; PSUMMIT-1 and 2 Study Groups.
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic
progression in patients with active psoriatic arthritis: results of an integrated
analysis of radiographic data from the phase 3, multicentre, randomised,
double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis.
2014 Jun;73(6):1000-6. doi: 10.1136/annrheumdis-2013-204741. Epub 2014 Feb 19.
PubMed PMID: 24553909; PubMed Central PMCID: PMC4033146.


37: Kavanaugh A, McInnes IB, Mease PJ, Krueger GG, Gladman DD, van der Heijde D, 
Mudivarthy S, Xu W, Mack M, Xu Z, Beutler A. Clinical efficacy, radiographic and 
safety findings through 2 years of golimumab treatment in patients with active
psoriatic arthritis: results from a long-term extension of the randomised,
placebo-controlled GO-REVEAL study. Ann Rheum Dis. 2013 Nov;72(11):1777-85. doi: 
10.1136/annrheumdis-2012-202035. Epub 2012 Nov 17. PubMed PMID: 23161902; PubMed 
Central PMCID: PMC3812864.


38: Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani 
PM. The effects of adalimumab treatment and psoriasis severity on self-reported
work productivity and activity impairment for patients with moderate to severe
psoriasis. J Am Acad Dermatol. 2012 Feb;66(2):e67-76. doi:
10.1016/j.jaad.2010.10.020. Epub 2011 May 25. PubMed PMID: 21616560.


39: Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D,
Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group. 
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N
Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679. PubMed PMID:
26422723.


40: Rollefstad S, Ikdahl E, Hisdal J, Olsen IC, Holme I, Hammer HB, Smerud KT,
Kitas GD, Pedersen TR, Kvien TK, Semb AG. Rosuvastatin-Induced Carotid Plaque
Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in
Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint
Diseases Study. Arthritis Rheumatol. 2015 Jul;67(7):1718-28. doi:
10.1002/art.39114. PubMed PMID: 25778850.


41: McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der 
Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G,
Patekar M, Mpofu S; FUTURE 2 Study Group. Secukinumab, a human
anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis
(FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub
2015 Jun 28. PubMed PMID: 26135703.


42: Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M,
Tandon N, Han C, Mease P. Patient-reported outcomes and the association with
clinical response in patients with active psoriatic arthritis treated with
golimumab: findings through 2 years of a phase III, multicenter, randomized,
double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2013
Oct;65(10):1666-73. doi: 10.1002/acr.22044. PubMed PMID: 23666608; PubMed Central
PMCID: PMC4282022.


43: Husni ME, Qureshi AA, Koenig AS, Pedersen R, Robertson D. Utility of the PASE
questionnaire, psoriatic arthritis (PsA) prevalence and PsA improvement with
anti-TNF therapy: results from the PRISTINE trial. J Dermatolog Treat. 2014
Feb;25(1):90-5. doi: 10.3109/09546634.2013.800185. Epub 2013 Jun 20. PubMed PMID:
23688125.


44: Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M. Disease activity 
in psoriatic arthritis: comparison of the discriminative capacity and construct
validity of six composite indices in a real world. Biomed Res Int.
2014;2014:528105. doi: 10.1155/2014/528105. Epub 2014 May 20. PubMed PMID:
24967375; PubMed Central PMCID: PMC4055291.


45: Osterhaus JT, Purcaru O. Discriminant validity, responsiveness and
reliability of the arthritis-specific Work Productivity Survey assessing
workplace and household productivity in patients with psoriatic arthritis.
Arthritis Res Ther. 2014 Jul 4;16(4):R140. doi: 10.1186/ar4602. PubMed PMID:
24996416; PubMed Central PMCID: PMC4226958.


46: Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak
J, Molta CT, Freundlich B. Comparison of two etanercept regimens for treatment of
psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre
trial. BMJ. 2010 Feb 2;340:c147. doi: 10.1136/bmj.c147. PubMed PMID: 20124563.


47: McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C,
Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group.
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1
year results of the phase 3, multicentre, double-blind, placebo-controlled
PSUMMIT 1 trial. Lancet. 2013 Aug 31;382(9894):780-9. doi:
10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13. PubMed PMID: 23769296.


48: Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk
VG, Dehoorne J, Panaviene V, Susic G, Stanevica V, Kobusinska K, Zuber Z, Mouy R,
Rumba-Rozenfelde I, Breda L, Dolezalova P, Job-Deslandre C, Wulffraat N, Alvarez 
D, Zang C, Wajdula J, Woodworth D, Vlahos B, Martini A, Ruperto N; Paediatric
Rheumatology International Trials Organisation (PRINTO). Efficacy and safety of
open-label etanercept on extended oligoarticular juvenile idiopathic arthritis,
enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the
CLIPPER study. Ann Rheum Dis. 2014 Jun;73(6):1114-22. doi:
10.1136/annrheumdis-2012-203046. Epub 2013 May 21. PubMed PMID: 23696632; PubMed 
Central PMCID: PMC4033142.


49: David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, Yankova R, 
Kouzeva V, Ramon M, Silverman MH, Fishman P. Treatment of plaque-type psoriasis
with oral CF101: data from an exploratory randomized phase 2 clinical trial. J
Eur Acad Dermatol Venereol. 2012 Mar;26(3):361-7. doi:
10.1111/j.1468-3083.2011.04078.x. Epub 2011 Apr 20. PubMed PMID: 21504485.


50: Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun 
J, Kavanaugh A. Golimumab 3-year safety update: an analysis of pooled data from
the long-term extensions of randomised, double-blind, placebo-controlled trials
conducted in patients with rheumatoid arthritis, psoriatic arthritis or
ankylosing spondylitis. Ann Rheum Dis. 2015 Mar;74(3):538-46. doi:
10.1136/annrheumdis-2013-204195. Epub 2013 Dec 16. PubMed PMID: 24344160; PubMed 
Central PMCID: PMC4345908.


51: Tamayo M, Pértega S, Mosquera A, Rodríguez M, Blanco FJ, Fernández-Sueiro JL,
Gosálvez J, Fernández JL. Individual telomere length decay in patients with
spondyloarthritis. Mutat Res. 2014 Jul;765:1-5. doi:
10.1016/j.mrfmmm.2014.04.006. Epub 2014 Apr 24. PubMed PMID: 24769426.


52: Mease PJ, Heckaman M, Kary S, Kupper H. Application and modifications of
minimal disease activity measures for patients with psoriatic arthritis treated
with adalimumab: subanalyses of ADEPT. J Rheumatol. 2013 May;40(5):647-52. doi:
10.3899/jrheum.120970. Epub 2013 Mar 15. PubMed PMID: 23504383.


53: Chimenti MS, Triggianese P, Conigliaro P, Santoro M, Lucchetti R, Perricone
R. Self-reported adherence to a home-based exercise program among patients
affected by psoriatic arthritis with minimal disease activity. Drug Dev Res. 2014
Nov;75 Suppl 1:S57-9. doi: 10.1002/ddr.21197. PubMed PMID: 25381979.


54: Schafer PH, Chen P, Fang L, Wang A, Chopra R. The pharmacodynamic impact of
apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of
inflammatory biomarkers in patients with psoriatic arthritis: substudy results
from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res.
2015;2015:906349. doi: 10.1155/2015/906349. Epub 2015 Apr 20. PubMed PMID:
25973439; PubMed Central PMCID: PMC4417944.


55: Coates LC, Navarro-Coy N, Brown SR, Brown S, McParland L, Collier H, Skinner 
E, Law J, Moverley A, Pavitt S, Hulme C, Emery P, Conaghan PG, Helliwell PS. The 
TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled
trial to compare intensive management versus standard care in early psoriatic
arthritis. BMC Musculoskelet Disord. 2013 Mar 21;14:101. doi:
10.1186/1471-2474-14-101. PubMed PMID: 23517506; PubMed Central PMCID:
PMC3610193.


56: de Groot M, Picavet DI, van Kuijk AW, Tak PP, Bos JD, de Rie MA, Teunissen
MB. A prospective, randomized, placebo-controlled study to identify biomarkers
associated with active treatment in psoriatic arthritis: effects of adalimumab
treatment on lesional and nonlesional skin. Dermatology. 2012;225(4):298-303.
doi: 10.1159/000343290. Epub 2012 Dec 21. PubMed PMID: 23257348.


57: Sojević Timotijević Z, Janković S, Trajković G, Majcan P, Perišić S, Dostanić
N, Janićijević Hudomal S, Janković J. Identification of psoriatic patients at
risk of high quality of life impairment. J Dermatol. 2013 Oct;40(10):797-804.
doi: 10.1111/1346-8138.12201. Epub 2013 Aug 21. PubMed PMID: 23961725.


58: Husic R, Gretler J, Felber A, Graninger WB, Duftner C, Hermann J, Dejaco C.
Disparity between ultrasound and clinical findings in psoriatic arthritis. Ann
Rheum Dis. 2014 Aug;73(8):1529-36. doi: 10.1136/annrheumdis-2012-203073. Epub
2013 Jun 5. PubMed PMID: 23740228.


59: Helliwell PS, Kavanaugh A. Comparison of composite measures of disease
activity in psoriatic arthritis using data from an interventional study with
golimumab. Arthritis Care Res (Hoboken). 2014 May;66(5):749-56. doi:
10.1002/acr.22204. PubMed PMID: 24127416.


60: Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A, Esposito M,
Tiberti S, Chimenti S, DE Lorenzo A. Prospective assessment of body weight and
body composition changes in patients with psoriasis receiving anti-TNF-α
treatment. Dermatol Ther. 2011 Jul-Aug;24(4):446-51. doi:
10.1111/j.1529-8019.2011.01439.x. PubMed PMID: 21910803.


61: Przepiera-Będzak H, Fischer K, Brzosko M. Serum levels of angiogenic
cytokines in psoriatic arthritis and SAPHO syndrome. Pol Arch Med Wewn.
2013;123(6):297-302. Epub 2013 May 27. PubMed PMID: 23711571.


62: Jimenez-Boj E, Stamm TA, Sadlonova M, Rovensky J, Raffayová H, Leeb B,
Machold KP, Graninger WB, Smolen JS. Rituximab in psoriatic arthritis: an
exploratory evaluation. Ann Rheum Dis. 2012 Nov;71(11):1868-71. doi:
10.1136/annrheumdis-2012-201897. Epub 2012 Jul 24. PubMed PMID: 22833373.


63: Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR,
Mulani PM. Efficacy and safety of adalimumab among patients with moderate to
severe psoriasis with co-morbidities: Subanalysis of results from a randomized,
double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol. 2011 Feb
1;12(1):51-62. doi: 10.2165/11530640-000000000-00000. PubMed PMID: 21110526.


64: Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R; CaRRDs 
Study Group. Weight loss and achievement of minimal disease activity in patients 
with psoriatic arthritis starting treatment with tumour necrosis factor α
blockers. Ann Rheum Dis. 2014 Jun;73(6):1157-62. doi:
10.1136/annrheumdis-2012-202812. Epub 2013 Jun 14. PubMed PMID: 23771989; PubMed 
Central PMCID: PMC4033114.


65: Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P. Improvements in
productivity at paid work and within the household, and increased participation
in daily activities after 24 weeks of certolizumab pegol treatment of patients
with psoriatic arthritis: results of a phase 3 double-blind randomised
placebo-controlled study. Ann Rheum Dis. 2015 Jan;74(1):44-51. doi:
10.1136/annrheumdis-2014-205198. Epub 2014 Jun 18. PubMed PMID: 24942382; PubMed 
Central PMCID: PMC4283690.


66: McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen
G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP,
Hueber W, Tak PP. Efficacy and safety of secukinumab, a fully human
anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe
psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled,
phase II proof-of-concept trial. Ann Rheum Dis. 2014 Feb;73(2):349-56. doi:
10.1136/annrheumdis-2012-202646. Epub 2013 Jan 29. PubMed PMID: 23361084.


67: Gladman DD, Abufayyah M, Salonen D, Thavaneswaran A, Chandran V. Radiological
characteristics of the calcaneal spurs in psoriatic arthritis. Clin Exp
Rheumatol. 2014 May-Jun;32(3):401-3. Epub 2014 May 12. Erratum in: Clin Exp
Rheumatol. 2014 Nov-Dec;32(6):996. Abuffayah, M [corrected to Abufayyah, M].
PubMed PMID: 24850064.


68: Braun J, Rudwaleit M, Kary S, Kron M, Wong RL, Kupper H. Clinical
manifestations and responsiveness to adalimumab are similar in patients with
ankylosing spondylitis with and without concomitant psoriasis. Rheumatology
(Oxford). 2010 Aug;49(8):1578-89. doi: 10.1093/rheumatology/keq129. Epub 2010 May
6. PubMed PMID: 20448079.


69: Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A,
Newmark R, Feng J, Erondu N, Nirula A. Brodalumab, an anti-IL17RA monoclonal
antibody, in psoriatic arthritis. N Engl J Med. 2014 Jun 12;370(24):2295-306.
doi: 10.1056/NEJMoa1315231. PubMed PMID: 24918373.


70: Wang YN, Zhang Y, Wang Y, Zhu DX, Xu LQ, Fang H, Wu W. The beneficial effect 
of total glucosides of paeony on psoriatic arthritis links to circulating Tregs
and Th1 cell function. Phytother Res. 2014 Mar;28(3):372-81. doi:
10.1002/ptr.5005. Epub 2013 Apr 23. PubMed PMID: 23610010.


71: Gladman D, Fleischmann R, Coteur G, Woltering F, Mease PJ. Effect of
certolizumab pegol on multiple facets of psoriatic arthritis as reported by
patients: 24-week patient-reported outcome results of a phase III, multicenter
study. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1085-92. doi:
10.1002/acr.22256. PubMed PMID: 24339179; PubMed Central PMCID: PMC4171746.


72: Hoff M, Kavanaugh A, Haugeberg G. Hand bone loss in patients with psoriatic
arthritis: posthoc analysis of IMPACT II data comparing infliximab and placebo. J
Rheumatol. 2013 Aug;40(8):1344-8. doi: 10.3899/jrheum.121376. Epub 2013 Jun 15.
PubMed PMID: 23772084.


73: Paramarta JE, De Rycke L, Heijda TF, Ambarus CA, Vos K, Dinant HJ, Tak PP,
Baeten DL. Efficacy and safety of adalimumab for the treatment of peripheral
arthritis in spondyloarthritis patients without ankylosing spondylitis or
psoriatic arthritis. Ann Rheum Dis. 2013 Nov;72(11):1793-9. doi:
10.1136/annrheumdis-2012-202245. Epub 2012 Nov 8. PubMed PMID: 23139265.


74: van der Heijde D, Fleischmann R, Wollenhaupt J, Deodhar A, Kielar D,
Woltering F, Stach C, Hoepken B, Arledge T, Mease PJ. Effect of different
imputation approaches on the evaluation of radiographic progression in patients
with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind
randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014
Jan;73(1):233-7. doi: 10.1136/annrheumdis-2013-203697. Epub 2013 Aug 13. PubMed
PMID: 23942869; PubMed Central PMCID: PMC3888591.


75: Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG,
Murphy FT, Papp K, Gomez-Reino JJ, Mack M, Beutler A, Gladman D, Kavanaugh A.
Markers of inflammation and bone remodelling associated with improvement in
clinical response measures in psoriatic arthritis patients treated with
golimumab. Ann Rheum Dis. 2013 Jan;72(1):83-8. doi:
10.1136/annrheumdis-2012-201697. Epub 2012 Sep 12. PubMed PMID: 22975755; PubMed 
Central PMCID: PMC3551220.


76: Glintborg B, Gudbjornsson B, Krogh NS, Omerovic E, Manilo N, Holland-Fischer 
M, Lindegaard HM, Loft AG, Nordin H, Johnsen L, Oeftiger SF, Hansen A, Rasmussen 
C, Grondal G, Geirsson AJ, Hetland ML. Impact of different infliximab dose
regimens on treatment response and drug survival in 462 patients with psoriatic
arthritis: results from the nationwide registries DANBIO and ICEBIO. Rheumatology
(Oxford). 2014 Nov;53(11):2100-9. doi: 10.1093/rheumatology/keu252. Epub 2014 Jun
17. PubMed PMID: 24939677.


77: Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and
psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis.
Department of Veterans Affairs Cooperative Study Group on Seronegative
Spondyloarthropathies. J Rheumatol. 1999 Aug;26(8):1752-6. PubMed PMID: 10451073.


78: FitzGerald O, Helliwell P, Mease P, Mumtaz A, Coates L, Pedersen R, Nab H,
Molta C. Application of composite disease activity scores in psoriatic arthritis 
to the PRESTA data set. Ann Rheum Dis. 2012 Mar;71(3):358-62. doi:
10.1136/annrheumdis-2011-200093. Epub 2011 Oct 11. PubMed PMID: 21989542.


79: Otten MH, Prince FH, Ten Cate R, van Rossum MA, Twilt M, Hoppenreijs EP,
Koopman-Keemink Y, Oranje AP, de Waard-van der Spek FB, Gorter SL, Armbrust W,
Dolman KM, Wulffraat NM, van Suijlekom-Smit LW. Tumour necrosis factor
(TNF)-blocking agents in juvenile psoriatic arthritis: are they effective? Ann
Rheum Dis. 2011 Feb;70(2):337-40. doi: 10.1136/ard.2010.135731. Epub 2010 Nov 10.
PubMed PMID: 21068101.


80: O'Daly JA, Gleason J, Lezama R, Rodriguez PJ, Silva E, Indriago NR. Antigens 
from Leishmania amastigotes inducing clinical remission of psoriatic arthritis.
Arch Dermatol Res. 2011 Aug;303(6):399-415. doi: 10.1007/s00403-011-1133-0. Epub 
2011 Feb 17. PubMed PMID: 21328087.


81: Rigopoulos D, Gregoriou S, Lazaridou E, Belyayeva E, Apalla Z, Makris M,
Katsambas A, Ioannides D. Treatment of nail psoriasis with adalimumab: an open
label unblinded study. J Eur Acad Dermatol Venereol. 2010 May;24(5):530-4. doi:
10.1111/j.1468-3083.2009.03453.x. Epub 2009 Oct 6. PubMed PMID: 19807825.


82: Strand V, Schett G, Hu C, Stevens RM. Patient-reported Health-related Quality
of Life with apremilast for psoriatic arthritis: a phase II, randomized,
controlled study. J Rheumatol. 2013 Jul;40(7):1158-65. doi:
10.3899/jrheum.121200. Epub 2013 Apr 15. PubMed PMID: 23588944.


83: Schäfer VS, Fleck M, Kellner H, Strunk J, Sattler H, Schmidt WA, Ehrenstein
B, Backhaus M, Hartung W. Evaluation of the novel ultrasound score for large
joints in psoriatic arthritis and ankylosing spondylitis: six month experience in
daily clinical practice. BMC Musculoskelet Disord. 2013 Dec 19;14:358. doi:
10.1186/1471-2474-14-358. PubMed PMID: 24351026; PubMed Central PMCID:
PMC3878335.


84: Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F.
Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic
arthritis. Br J Dermatol. 2008 Aug;159(2):322-30. doi:
10.1111/j.1365-2133.2008.08628.x. Epub 2008 May 22. PubMed PMID: 18503600.


85: Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in
the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet.
2000 Jul 29;356(9227):385-90. PubMed PMID: 10972371.


86: Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A,
Bianchi L, Chimenti S. Adalimumab for severe psoriasis and psoriatic arthritis:
an open-label study in 30 patients previously treated with other biologics. J Am 
Acad Dermatol. 2007 Aug;57(2):269-75. Epub 2007 Jun 18. PubMed PMID: 17574299.


87: Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha
levels in patients with psoriatic arthritis undergoing etanercept treatment. J
Interferon Cytokine Res. 2012 Jun;32(6):277-9. doi: 10.1089/jir.2011.0120. Epub
2012 Apr 5. PubMed PMID: 22480318.


88: Ciancio G, Volpinari S, Fotinidi M, Furini F, Farina I, Bortoluzzi A,
Ferracin M, Bandinelli F, Orzincolo C, Trotta F, Govoni M. Involvement of the
inconstant bursa of the fifth metatarsophalangeal joint in psoriatic arthritis: a
clinical and ultrasonographic study. Biomed Res Int. 2014;2014:174841. doi:
10.1155/2014/174841. Epub 2014 Jul 1. PubMed PMID: 25061602; PubMed Central
PMCID: PMC4100366.


89: Möller I, Pérez M, Monfort J, Benito P, Cuevas J, Perna C, Doménech G,
Herrero M, Montell E, Vergés J. Effectiveness of chondroitin sulphate in patients
with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind,
placebo-controlled study. Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1:S32-40.
doi: 10.1016/j.joca.2010.01.018. Epub 2010 May 10. PubMed PMID: 20399899.


90: Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, Wollenhaupt
J, Bahary O, Becker JC, Kelly S, Sigal L, Teng J, Gladman D. Abatacept in the
treatment of patients with psoriatic arthritis: results of a six-month,
multicenter, randomized, double-blind, placebo-controlled, phase II trial.
Arthritis Rheum. 2011 Apr;63(4):939-48. doi: 10.1002/art.30176. PubMed PMID:
21128258.


91: Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, de Rie MA, Bos JD, Tak PP.
Early effects of tumour necrosis factor alpha blockade on skin and synovial
tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis. 
2004 Jul;63(7):769-73. PubMed PMID: 15194570; PubMed Central PMCID: PMC1755073.


92: Mazzoccoli G, Notarsanto I, de Pinto GD, Dagostino MP, De Cata A,
D'Alessandro G, Tarquini R, Vendemiale G. Anti-tumor necrosis factor-α therapy
and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis
patients. Intern Emerg Med. 2010 Dec;5(6):495-500. doi:
10.1007/s11739-010-0458-6. Epub 2010 Sep 16. Erratum in: Intern Emerg Med. 2011
Feb;6(1):97. PubMed PMID: 20845087.


93: Baranauskaite A, Raffayová H, Kungurov NV, Kubanova A, Venalis A, Helmle L,
Srinivasan S, Nasonov E, Vastesaeger N; RESPOND investigators. Infliximab plus
methotrexate is superior to methotrexate alone in the treatment of psoriatic
arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012 
Apr;71(4):541-8. doi: 10.1136/ard.2011.152223. Epub 2011 Oct 12. PubMed PMID:
21994233; PubMed Central PMCID: PMC3298666.


94: Nash P, Thaçi D, Behrens F, Falk F, Kaltwasser JP. Leflunomide improves
psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from
the TOPAS study. Dermatology. 2006;212(3):238-49. PubMed PMID: 16549920.


95: Bongiorno MR, Pistone G, Doukaki S, Aricò M. Adalimumab for treatment of
moderate to severe psoriasis and psoriatic arthritis. Dermatol Ther. 2008 Oct;21 
Suppl 2:S15-20. doi: 10.1111/j.1529-8019.2008.00227.x. PubMed PMID: 18837728.


96: Tak PP, Bacchi M, Bertolino M. Pharmacokinetics of IL-18 binding protein in
healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis.
Eur J Drug Metab Pharmacokinet. 2006 Apr-Jun;31(2):109-16. PubMed PMID: 16898079.


97: Karanikolas GN, Koukli EM, Katsalira A, Arida A, Petrou D, Komninou E,
Fragiadaki K, Zacharioudaki A, Lasithiotakis I, Giavri E, Vaiopoulos G, Sfikakis 
PP. Adalimumab or cyclosporine as monotherapy and in combination in severe
psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded 
clinical trial. J Rheumatol. 2011 Nov;38(11):2466-74. doi: 10.3899/jrheum.110242.
Epub 2011 Sep 1. PubMed PMID: 21885499.


98: Moraitis AG, Freeman LA, Shamburek RD, Wesley R, Wilson W, Grant CM, Price S,
Demosky S, Thacker SG, Zarzour A, Hornung RL, Pucino F, Csako G, Yarboro C,
McInnes IB, Kuroiwa T, Boumpas D, Rao VK, Illei GG, Remaley AT. Elevated
interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency. J
Clin Lipidol. 2015 Jan-Feb;9(1):81-90. doi: 10.1016/j.jacl.2014.09.014. Epub 2014
Oct 5. PubMed PMID: 25670364.


99: Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of 
psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor
inhibitor infliximab. Rheumatol Int. 2002 Nov;22(6):227-32. Epub 2002 Sep 4.
PubMed PMID: 12426660.


100: Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, Bensen 
W, Syrotuik J, Poulin-Costello M. Effectiveness and safety of etanercept in
patients with psoriatic arthritis in a Canadian clinical practice setting: the
REPArE trial. J Rheumatol. 2011 Jul;38(7):1355-62. doi: 10.3899/jrheum.100698.
Epub 2011 May 15. PubMed PMID: 21572156.


101: Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P.
Antibody response is reduced following vaccination with 7-valent conjugate
pneumococcal vaccine in adult methotrexate-treated patients with established
arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis
Rheum. 2011 Dec;63(12):3723-32. doi: 10.1002/art.30580. PubMed PMID: 21834061.


102: Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tumor necrosis
factor inhibitors: longer-term outcomes including enthesitis and dactylitis with 
golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled
Study (GO-REVEAL). J Rheumatol Suppl. 2012 Jul;89:90-3. doi:
10.3899/jrheum.120254. PubMed PMID: 22751603.


103: Fiocco U, Oliviero F, Sfriso P, Calabrese F, Lunardi F, Scagliori E,
Rubaltelli L, Stramare R, Di Maggio A, Nardacchione R, Cozzi L, Molena B,
Felicetti M, Gazzola K, Lo Nigro A, Accordi B, Roux-Lombard P, Dayer JM, Punzi L.
Synovial biomarkers in psoriatic arthritis. J Rheumatol Suppl. 2012 Jul;89:61-4. 
doi: 10.3899/jrheum.120246. PubMed PMID: 22751595.


104: Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, 
Gómez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, 
Zrubek J, Beutler A. Golimumab in psoriatic arthritis: one-year clinical
efficacy, radiographic, and safety results from a phase III, randomized,
placebo-controlled trial. Arthritis Rheum. 2012 Aug;64(8):2504-17. doi:
10.1002/art.34436. PubMed PMID: 22378566.


105: Lassus A, Dahlgren AL, Halpern MJ, Santalahti J, Happonen HP. Effects of
dietary supplementation with polyunsaturated ethyl ester lipids (Angiosan) in
patients with psoriasis and psoriatic arthritis. J Int Med Res. 1990
Jan-Feb;18(1):68-73. PubMed PMID: 2139859.


106: Chimenti MS, Teoli M, Saraceno R, Dattola A, Ventura A, Chiricozzi A,
Chiaramonte C, Perricone R, Chimenti S. Golimumab in patients affected by
moderate to severe psoriatic arthritis: an open-label study in thirty-two
patients previously treated with other biologics. Dermatology.
2013;227(4):305-10. doi: 10.1159/000354263. Epub 2013 Nov 19. PubMed PMID:
24280959.


107: Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C,
Ujfalussy I, Scarpa R, Marchesoni A, Taylor WJ, Spadaro A, Fernàndez-Sueiro JL,
Salvarani C, Kalden JR, Lubrano E, Carneiro S, Desiati F, Flynn JA, D'Angelo S,
Vacca A, VAN Kuijk AW, Catanoso MG, Gruenke M, Peluso R, Parsons WJ, Ferrara N,
Contu P, Helliwell PS, Mease PJ; GRAPPA 3PPsA Study Group. Patient global
assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J
Rheumatol. 2011 May;38(5):898-903. doi: 10.3899/jrheum.100857. Epub 2011 Feb 15. 
PubMed PMID: 21324965.


108: Zbojanová M, Vlcek F, Trnavský K. [Our experience of psoriatic arthritis and
psoriasis treatment with methotrexate (author's transl)]. Cesk Dermatol. 1980
Feb;55(1):39-44. Slovak. PubMed PMID: 6988086.


109: Barbero-Villares A, Mendoza J, Trapero-Marugan M, Gonzalez-Alvaro I, Daudén 
E, Gisbert JP, Moreno-Otero R. Evaluation of liver fibrosis by transient
elastography in methotrexate treated patients. Med Clin (Barc). 2011 Nov
26;137(14):637-9. doi: 10.1016/j.medcli.2010.12.024. Epub 2011 Jun 29. PubMed
PMID: 21719043.


110: Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C,
Stevens R, de Vlam KL. Oral apremilast in the treatment of active psoriatic
arthritis: results of a multicenter, randomized, double-blind, placebo-controlled
study. Arthritis Rheum. 2012 Oct;64(10):3156-67. doi: 10.1002/art.34627. PubMed
PMID: 22806399.


111: Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt 
J, Falk FG, Mease P; Treatment of Psoriatic Arthritis Study Group. Efficacy and
safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a
multinational, double-blind, randomized, placebo-controlled clinical trial.
Arthritis Rheum. 2004 Jun;50(6):1939-50. PubMed PMID: 15188371.


112: Dawczynski C, Hackermeier U, Viehweger M, Stange R, Springer M, Jahreis G.
Incorporation of n-3 PUFA and γ-linolenic acid in blood lipids and red blood cell
lipids together with their influence on disease activity in patients with chronic
inflammatory arthritis--a randomized controlled human intervention trial. Lipids 
Health Dis. 2011 Aug 4;10:130. doi: 10.1186/1476-511X-10-130. PubMed PMID:
21816071; PubMed Central PMCID: PMC3162909.


113: Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Lüftl M.
Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody
clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J
Dermatol. 2001 Mar;144(3):587-9. PubMed PMID: 11260020.


114: Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate
mofetil treatment improves hypertension in patients with psoriasis and rheumatoid
arthritis. J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S218-25. PubMed PMID:
17130265.


115: Di Minno MN, Iervolino S, Peluso R, Russolillo A, Lupoli R, Scarpa R, Di
Minno G, Tarantino G; CaRRDS Study Group. Hepatic steatosis and disease activity 
in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers. 
J Rheumatol. 2012 May;39(5):1042-6. doi: 10.3899/jrheum.111391. Epub 2012 Mar 15.
PubMed PMID: 22422493.


116: Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ,
Mulherin DM, Kitas GD, Chakravarty K, Tom BD, O'Keeffe AG, Maddison PJ, Scott DL.
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.
Rheumatology (Oxford). 2012 Aug;51(8):1368-77. doi: 10.1093/rheumatology/kes001. 
Epub 2012 Feb 17. PubMed PMID: 22344575; PubMed Central PMCID: PMC3397466.


117: Mazzotta A, Esposito M, Costanzo A, Chimenti S. Efficacy and safety of
etanercept in psoriasis after switching from other treatments: an observational
study. Am J Clin Dermatol. 2009;10(5):319-24. doi:
10.2165/11310770-000000000-00000. PubMed PMID: 19658444.


118: Delle Sedie A, Riente L, Filippucci E, Scirè CA, Iagnocco A, Meenagh G,
Gutierrez M, Valesini G, Montecucco C, Grassi W, Bombardieri S. Ultrasound
imaging for the rheumatologist. XXXII. Sonographic assessment of the foot in
patients with psoriatic arthritis. Clin Exp Rheumatol. 2011 Mar-Apr;29(2):217-22.
Epub 2011 Apr 19. PubMed PMID: 21504659.


119: Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E,
Cardinale I, Lowes MA, Krueger JG. Effective treatment of psoriasis with
etanercept is linked to suppression of IL-17 signaling, not immediate response
TNF genes. J Allergy Clin Immunol. 2009 Nov;124(5):1022-10.e1-395. doi:
10.1016/j.jaci.2009.08.046. PubMed PMID: 19895991; PubMed Central PMCID:
PMC2852188.


120: Bachmann E, Clemmensen OJ, Dyrbye M, Larsen K. Joint involvement in
psoriasis: scintigraphic, radiologic and clinical findings. Dermatologica.
1983;166(5):250-4. PubMed PMID: 6873418.


121: Paul C, Solignac M. [Psoriasis and psoriatic rheumatism: effectiveness of
etanercept for cutaneous and joint lesions]. Ann Dermatol Venereol. 2010
Apr;137(4 Suppl):13-5. doi: 10.1016/S0151-9638(10)70012-0. French. PubMed PMID:
20510165.


122: Thami GP, Garg G. Leflunomide in psoriasis and psoriatic arthritis: a
preliminary study. Arch Dermatol. 2004 Oct;140(10):1288-9. PubMed PMID: 15492204.


123: Mease PJ. Etanercept, a TNF antagonist for treatment for psoriatic arthritis
and psoriasis. Skin Therapy Lett. 2003 Jan;8(1):1-4. PubMed PMID: 12728284.


124: Prignano F, Ruffo G, Ricceri F, Pescitelli L, Lotti T. A global approach to 
psoriatic patients through PASI score and Skindex-29. G Ital Dermatol Venereol.
2011 Feb;146(1):47-52. PubMed PMID: 21317856.


125: Iagnocco A, Spadaro A, Marchesoni A, Cauli A, De Lucia O, Gabba A, Takanen
S, Montepaone M, Perrotta FM, D'Agostino MA, Mathieu A, Valesini G. Power Doppler
ultrasonographic evaluation of enthesitis in psoriatic arthritis. A multi-center 
study. Joint Bone Spine. 2012 May;79(3):324-5. doi: 10.1016/j.jbspin.2011.10.005.
Epub 2011 Nov 26. PubMed PMID: 22119348.


126: Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, van
Vollenhoven RF, Leirisalo-Repo M, Fitzgerald O, Kron M, Frank M, Kary S, Kupper
H. Effectiveness of adalimumab in treating patients with active psoriatic
arthritis and predictors of good clinical responses for arthritis, skin and nail 
lesions. Ann Rheum Dis. 2010 Feb;69(2):394-9. doi: 10.1136/ard.2009.111856. Epub 
2009 Oct 7. PubMed PMID: 19815494; PubMed Central PMCID: PMC2800202.


127: Gladman DD; ACCLAIM Study Investigators, Sampalis JS, Illouz O, Guérette B. 
Responses to adalimumab in patients with active psoriatic arthritis who have not 
adequately responded to prior therapy: effectiveness and safety results from an
open-label study. J Rheumatol. 2010 Sep;37(9):1898-906. doi:
10.3899/jrheum.100069. Epub 2010 Jul 1. PubMed PMID: 20595284.


128: Migliore A, Bizzi E, Broccoli S, Laganà B. Indirect comparison of
etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment
comparison using placebo as common comparator. Clin Rheumatol. 2012
Jan;31(1):133-7. doi: 10.1007/s10067-011-1790-6. Epub 2011 Jun 24. PubMed PMID:
21701796.


129: Cassano N, Galluccio A, De Simone C, Loconsole F, Massimino SD, Plumari A,
Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pita O, Fenizi G, Altamura
V, Congedo M, Pellicano R, Vena GA. Influence of body mass index, comorbidities
and prior systemic therapies on the response of psoriasis to adalimumab: an
exploratory analysis from the APHRODITE data. J Biol Regul Homeost Agents. 2008
Oct-Dec;22(4):233-7. PubMed PMID: 19036225.


130: Levell NJ, Shuster S, Munro CS, Friedmann PS. Remission of ordinary
psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol. 
1995 Jan;75(1):65-9. PubMed PMID: 7747540.


131: Koskelo P, Kekki M, Virkkunen M, Lassus A, Somer T. Serum ceruloplasmin
concentration in rheumatoid arthritis, ankylosing spondylitis, psoriasis and
sarcoidosis. Acta Rheumatol Scand. 1966;12(4):261-6. PubMed PMID: 5336014.


132: Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA.
Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study.
Br J Rheumatol. 1990 Feb;29(1):46-9. PubMed PMID: 1968355.


133: Mahrle G, Schulze HJ, Färber L, Weidinger G, Steigleder GK. Low-dose
short-term cyclosporine versus etretinate in psoriasis: improvement of skin,
nail, and joint involvement. J Am Acad Dermatol. 1995 Jan;32(1):78-88. PubMed
PMID: 7822521.


134: Voulgari PV, Venetsanopoulou AI, Epagelis EK, Alamanos Y, Takalou I, Drosos 
AA. Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year 
experience. Ann Rheum Dis. 2007 Feb;66(2):270-1. Epub 2006 Oct 26. PubMed PMID:
17068063; PubMed Central PMCID: PMC1798489.


135: Cassano N, Loconsole F, Amoruso A, Coviello C, Filieri M, Filotico R, Del
Vecchio S, Vena GA. Infliximab monotherapy for refractory psoriasis: preliminary 
results. Int J Immunopathol Pharmacol. 2004 Sep-Dec;17(3):373-80. PubMed PMID:
15461871.


136: Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally
important difference of Health Assessment Questionnaire in psoriatic arthritis:
relating thresholds of improvement in functional ability to patient-rated
importance and satisfaction. J Rheumatol. 2011 Nov;38(11):2461-5. doi:
10.3899/jrheum.110546. Epub 2011 Sep 1. PubMed PMID: 21885498.


137: Fierlbeck G, Rassner G. Treatment of psoriasis and psoriatic arthritis with 
interferon gamma. J Invest Dermatol. 1990 Dec;95(6 Suppl):138S-141S. PubMed PMID:
2124243.


138: Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB. Effect of 
ustekinumab on physical function and health-related quality of life in patients
with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr 
Med Res Opin. 2010 Oct;26(10):2385-92. doi: 10.1185/03007995.2010.515804. PubMed 
PMID: 20831455.


139: Zhu YW, Mendelsohn A, Pendley C, Davis HM, Zhou H. Population
pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. Int 
J Clin Pharmacol Ther. 2010 Dec;48(12):830-46. PubMed PMID: 21084039.


140: Bøyesen P, McQueen FM, Gandjbakhch F, Lillegraven S, Coates L, Wiell C,
Haavardsholm EA, Conaghan PG, Peterfy CG, Bird P, Ostergaard M. The OMERACT
Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) is reliable and
sensitive to change: results from an OMERACT workshop. J Rheumatol. 2011
Sep;38(9):2034-8. doi: 10.3899/jrheum.110420. PubMed PMID: 21885513.


141: McQueen F, Lloyd R, Doyle A, Robinson E, Lobo M, Exeter M, Taylor WJ, Jones 
P, Reid IR, Dalbeth N. Zoledronic acid does not reduce MRI erosive progression in
PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis
(ZAPA) Study. Ann Rheum Dis. 2011 Jun;70(6):1091-4. doi: 10.1136/ard.2010.142539.
Epub 2011 Feb 22. PubMed PMID: 21342915.


142: Roth PE, Grosshans E, Bergoend H. [Psoriasis: development and fatal
complications]. Ann Dermatol Venereol. 1991;118(2):97-105. Review. French. PubMed
PMID: 2048897.


143: Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic
risk factors and the metabolic syndrome in patients with chronic inflammatory
arthritis. Arthritis Care Res (Hoboken). 2011 Feb;63(2):195-202. doi:
10.1002/acr.20363. PubMed PMID: 20890981.


144: Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley
LT, Menter A. Infliximab improves health-related quality of life in the presence 
of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol.
2008 Sep;159(3):704-10. doi: 10.1111/j.1365-2133.2008.08727.x. Epub 2008 Jul 9.
PubMed PMID: 18627375.


145: Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U,
Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R,
Wallace DJ, Weisman MH, Kalden JR, Smolen J. Sustained benefits of infliximab
therapy for dermatologic and articular manifestations of psoriatic arthritis:
results from the infliximab multinational psoriatic arthritis controlled trial
(IMPACT). Arthritis Rheum. 2005 Apr;52(4):1227-36. Erratum in: Arthritis Rheum.
2005 Sep;52(9):2951. PubMed PMID: 15818699.


146: De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S. High-dose
initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy,
safety and impact on patients' quality of life. J Dermatolog Treat.
2006;17(6):355-8. PubMed PMID: 17853309.


147: da Silva BS, Bonfá E, de Moraes JC, Saad CG, Ribeiro AC, Gonçalves CR, de
Carvalho JF. Effects of anti-TNF therapy on glucose metabolism in patients with
ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
Biologicals. 2010 Sep;38(5):567-9. doi: 10.1016/j.biologicals.2010.05.003. Epub
2010 Jul 16. PubMed PMID: 20638299.


148: Scarpa R, Atteno M, Lubrano E, Provenzano G, D'Angelo S, Spadaro A, Costa L,
Olivieri I. The effectiveness and safety of TNF-alpha blockers in the treatment
of early psoriatic arthritis: an Italian multicentre longitudinal observational
pilot study. Clin Rheumatol. 2011 Aug;30(8):1063-7. doi:
10.1007/s10067-011-1680-y. Epub 2011 Mar 1. PubMed PMID: 21360007; PubMed Central
PMCID: PMC3145085.


149: Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Treatment 
of psoriatic arthritis with sulphasalazine: a one year open study. Clin
Rheumatol. 1988 Sep;7(3):372-7. PubMed PMID: 2906579.


150: Leung YY, Zhu TY, Tam LS, Kun EW, Li EK. Minimal important difference and
responsiveness to change of the SF-36 in patients with psoriatic arthritis
receiving tumor necrosis factor-α blockers. J Rheumatol. 2011 Sep;38(9):2077-9.
doi: 10.3899/jrheum.101256. PubMed PMID: 21885524.


151: Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS.
Application of the DAREA/DAPSA score for assessment of disease activity in
psoriatic arthritis. Ann Rheum Dis. 2010 Aug;69(8):1441-7. doi:
10.1136/ard.2009.122259. Epub 2010 Jun 4. PubMed PMID: 20525844.


152: Dequeker J, Verdickt W, Gevers G, Vanschoubroek K. Longterm experience with 
oral gold in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol. 1984
Mar;3 Suppl 1:67-74. PubMed PMID: 6432416.


153: Fierlbeck G, Rassner G, Müller C. Psoriasis induced at the injection site of
recombinant interferon gamma. Results of immunohistologic investigations. Arch
Dermatol. 1990 Mar;126(3):351-5. PubMed PMID: 2106838.


154: Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.
Impact of adalimumab treatment on health-related quality of life and other
patient-reported outcomes: results from a 16-week randomized controlled trial in 
patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008
Mar;158(3):549-57. Epub 2007 Nov 28. PubMed PMID: 18047521.


155: Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of 
erythrodermic psoriasis with etanercept. Br J Dermatol. 2006 Jul;155(1):156-9.
PubMed PMID: 16792768.


156: Pontifex EK, Gerlag DM, Gogarty M, Vinkenoog M, Gibbs A, Burgman I, Fearon
U, Bresnihan B, Tak PP, Gibney RG, Veale DJ, FitzGerald O. Change in CD3 positive
T-cell expression in psoriatic arthritis synovium correlates with change in DAS28
and magnetic resonance imaging synovitis scores following initiation of biologic 
therapy--a single centre, open-label study. Arthritis Res Ther. 2011 Jan
27;13(1):R7. doi: 10.1186/ar3228. PubMed PMID: 21272347; PubMed Central PMCID:
PMC3241351.


157: Duvic M, Crane MM, Conant M, Mahoney SE, Reveille JD, Lehrman SN. Zidovudine
improves psoriasis in human immunodeficiency virus-positive males. Arch Dermatol.
1994 Apr;130(4):447-51. PubMed PMID: 7909423.


158: Levine S, Paulus HE. Treatment of psoriatic arthritis with azaribine.
Arthritis Rheum. 1976 Jan-Feb;19(1):21-8. PubMed PMID: 766762.


159: Angel K, Provan SA, Hammer HB, Mowinckel P, Kvien TK, Atar D. Changes in
arterial stiffness during continued infliximab treatment in patients with
inflammatory arthropathies. Fundam Clin Pharmacol. 2011 Aug;25(4):511-7. doi:
10.1111/j.1472-8206.2010.00872.x. Epub 2010 Sep 6. PubMed PMID: 20825487.


160: Carette S, Calin A, McCafferty JP, Wallin BA. A double-blind
placebo-controlled study of auranofin in patients with psoriatic arthritis.
Arthritis Rheum. 1989 Feb;32(2):158-65. PubMed PMID: 2645874.


161: Lonauer G, Wirth W. [Controlled double blind study on the effectiveness and 
adverse effects of acemetacin and indomethacin in the treatment of psoriatic
arthritis]. Arzneimittelforschung. 1980;30(8A):1440-4. German. PubMed PMID:
7191313.


162: Dorwart BB, Gall EP, Schumacher HR, Krauser RE. Chrysotherapy in psoriatic
arthritis. Efficacy and toxicity compared to rheumatoid arthritis. Arthritis
Rheum. 1978 Jun;21(5):513-5. PubMed PMID: 96841.


163: Seideman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral
colchicine. J Rheumatol. 1987 Aug;14(4):777-9. PubMed PMID: 3668983.


164: Dockx P, Decree J, Degreef H. Inhibition of the metabolism of endogenous
retinoic acid as treatment for severe psoriasis: an open study with oral
liarozole. Br J Dermatol. 1995 Sep;133(3):426-32. PubMed PMID: 8546999.


165: Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A,
Lubrano E, Del Puente A, Scarpa R. Comparison of effectiveness and safety of
infliximab, etanercept, and adalimumab in psoriatic arthritis patients who
experienced an inadequate response to previous disease-modifying antirheumatic
drugs. Clin Rheumatol. 2010 Apr;29(4):399-403. doi: 10.1007/s10067-009-1340-7.
PubMed PMID: 20066450.


166: Delle Sedie A, Riente L, Filippucci E, Scirè CA, Iagnocco A, Gutierrez M,
Valesini G, Montecucco C, Grassi W, Bombardieri S. Ultrasound imaging for the
rheumatologist XXVI. Sonographic assessment of the knee in patients with
psoriatic arthritis. Clin Exp Rheumatol. 2010 Mar-Apr;28(2):147-52. Epub 2010 May
13. PubMed PMID: 20483039.


167: Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F,
Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD. Adalimumab for
long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab
Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009
May;68(5):702-9. doi: 10.1136/ard.2008.092767. Epub 2008 Aug 6. PubMed PMID:
18684743; PubMed Central PMCID: PMC2663711.


168: Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ,
Cathcart ES, Samuelson CO Jr, Solsky MA, Kaplan SB, et al. Randomized,
double-blind, placebo controlled trial of low-dose pulse methotrexate in
psoriatic arthritis. Arthritis Rheum. 1984 Apr;27(4):376-81. PubMed PMID:
6712754.


169: Vergés J, Montell E, Herrero M, Perna C, Cuevas J, Pérez M, Möller I.
Clinical and histopathological improvement of psoriasis with oral chondroitin
sulfate: a serendipitous finding. Dermatol Online J. 2005 Mar 1;11(1):31. PubMed 
PMID: 15748570.


170: Coates LC, Helliwell PS. Validation of minimal disease activity criteria for
psoriatic arthritis using interventional trial data. Arthritis Care Res
(Hoboken). 2010 Jul;62(7):965-9. doi: 10.1002/acr.20155. PubMed PMID: 20589696.


171: Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J. A pilot
study of pharmacokinetically guided dosing of oral methotrexate in the initial
phase of psoriasis treatment. J Eur Acad Dermatol Venereol. 2008 Jan;22(1):19-24.
Epub 2007 Nov 19. PubMed PMID: 18031504.


172: Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley
LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent
infliximab maintenance regimens over 1 year in the treatment of
moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007 Jan;56(1):31.e1-15.
Epub 2006 Sep 6. PubMed PMID: 17097378.


173: Hall GH, Jones BJ, Head AC, Jones VE. Intra-articular methotrexate. Clinical
and laboratory study in rheumatoid and psoriatic arthritis. Ann Rheum Dis. 1978
Aug;37(4):351-6. PubMed PMID: 356763; PubMed Central PMCID: PMC1000243.


174: Hagel S, Lindqvist E, Bremander A, Petersson IF. Team-based rehabilitation
improves long-term aerobic capacity and health-related quality of life in
patients with chronic inflammatory arthritis. Disabil Rehabil.
2010;32(20):1686-96. doi: 10.3109/09638281003649946. PubMed PMID: 20175678.


175: Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B,
Dooley LT, Kavanaugh A; IMPACT 2 Trial Investigators. Infliximab improves signs
and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum
Dis. 2005 Aug;64(8):1150-7. Epub 2005 Jan 27. PubMed PMID: 15677701; PubMed
Central PMCID: PMC1755609.


176: Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp 
K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A. Golimumab, a new
human tumor necrosis factor alpha antibody, administered every four weeks as a
subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and
safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009
Apr;60(4):976-86. doi: 10.1002/art.24403. Erratum in: Arthritis Rheum.2010
Aug;62(8):2555. PubMed PMID: 19333944.


177: Dantzig PI, McEvoy B, Mauro J, Rayhanzadeh S. Low dose azaribine in the
treatment of psoriasis. Br J Dermatol. 1974 Nov;91(5):573-7. PubMed PMID:
4611468.


178: Englbrecht M, Wang Y, Ronneberger M, Manger B, Vastesaeger N, Veale DJ,
Schett G. Measuring joint involvement in polyarticular psoriatic arthritis: an
introduction of alternatives. Arthritis Care Res (Hoboken). 2010
Jul;62(7):977-83. doi: 10.1002/acr.20161. PubMed PMID: 20191568.


179: Hopkins R, Bird HA, Jones H, Hill J, Surrall KE, Astbury C, Miller A, Wright
V. A double-blind controlled trial of etretinate (Tigason) and ibuprofen in
psoriatic arthritis. Ann Rheum Dis. 1985 Mar;44(3):189-93. PubMed PMID: 3883917; 
PubMed Central PMCID: PMC1001603.


180: Clemmensen OJ, Siggaard-Andersen J, Worm AM, Stahl D, Frost F, Bloch I.
Psoriatic arthritis treated with oral zinc sulphate. Br J Dermatol. 1980
Oct;103(4):411-5. PubMed PMID: 7002197.


181: Lassus A. A comparative pilot study of azapropazone and indomethacin in the 
treatment of psoriatic arthritis and Reiter's disease. Curr Med Res Opin.
1976;4(1):65-9. PubMed PMID: 770082.


182: Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D,
Rubenstein J, Sharp JT, Dunn M, Tsuji W. Continued inhibition of radiographic
progression in patients with psoriatic arthritis following 2 years of treatment
with etanercept. J Rheumatol. 2006 Apr;33(4):712-21. Epub 2006 Feb 1. PubMed
PMID: 16463435.


183: Burdeĭnyĭ AP, Sigidin IaA, Novoselova TM. [Treatment of psoriatic arthritis 
with gold salts (chrysotherapy)]. Ter Arkh. 1986;58(7):38-43. Russian. PubMed
PMID: 3532401.


184: O'Daly JA, Lezama R, Rodriguez PJ, Silva E, Indriago NR, Peña G, Colorado I,
Gleason J, Rodríguez B, Acuña L, Ovalles T. Antigens from Leishmania amastigotes 
induced clinical remission of psoriasis. Arch Dermatol Res. 2009 Jan;301(1):1-13.
doi: 10.1007/s00403-008-0883-9. Epub 2008 Sep 6. PubMed PMID: 18777031.


185: Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric
monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad
Dermatol. 2002 Jun;46(6):886-91. PubMed PMID: 12063486.


186: Ellis CN, Goldfarb MT, Roenigk HH Jr, Rosenbaum M, Wheeler S, Voorhees JJ.
Effects of oral meclofenamate therapy in psoriasis. J Am Acad Dermatol. 1986
Jan;14(1):49-52. PubMed PMID: 3512633.


187: Tsai TF, Liu MT, Liao YH, Licu D. Clinical effectiveness and safety
experience with efalizumab in the treatment of patients with moderate-to-severe
plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study. J
Eur Acad Dermatol Venereol. 2008 Mar;22(3):345-52. Epub 2007 Nov 14. PubMed PMID:
18005021.


188: Tabrizi M, Wang B, Lu H, Huang S, Bell G, Schwab G, Roskos L. Population
pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients
with inflammatory diseases. Inflamm Allergy Drug Targets. 2010 Sep;9(4):229-37.
PubMed PMID: 20860546.


189: Schulze HJ, Mahrle G. Gamma interferon and psoriasis. Lancet. 1986 Oct
18;2(8512):926-7. PubMed PMID: 2876361.


190: Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D,
Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis:
safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004
Jul;50(7):2264-72. PubMed PMID: 15248226.


191: Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and
safety of adalimumab in patients with ankylosing spondylitis or psoriatic
arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 
2010;12(3):R117. doi: 10.1186/ar3054. Epub 2010 Jun 16. PubMed PMID: 20553600;
PubMed Central PMCID: PMC2911911.


192: Mease P, Sieper J, Van den Bosch F, Rahman P, Karunaratne PM, Pangan AL.
Randomized controlled trial of adalimumab in patients with nonpsoriatic
peripheral spondyloarthritis. Arthritis Rheumatol. 2015 Apr;67(4):914-23. doi:
10.1002/art.39008. PubMed PMID: 25545240; PubMed Central PMCID: PMC4409087.


193: Rosenthal M. A critical review of the effect of levamisole in rheumatic
diseases other than rheumatoid arthritis. J Rheumatol Suppl. 1978;4:97-100.
Review. PubMed PMID: 366146.


194: Daniliv LN. [Use of indomethacin in the treatment of psoriatic arthritis].
Reumatizam. 1978;25(3):79-81. Croatian. PubMed PMID: 353936.


195: Bird HA, Wright V. Psoriatic arthritis. Clin Rheum Dis. 1983
Dec;9(3):671-80. PubMed PMID: 6360520.


196: Tam LS, Li EK, Shang Q, Tomlinson B, Li M, Leung YY, Kuan WP, Kwok LW, Li
TK, Zhu Y, Kun EW, Yip G, Yu CM. Tumour necrosis factor alpha blockade is
associated with sustained regression of carotid intima-media thickness for
patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis.
2011 Apr;70(4):705-6. doi: 10.1136/ard.2010.131359. Epub 2010 Jul 20. PubMed
PMID: 20647274.


197: Atzeni F, Boccassini L, Antivalle M, Salaffi F, Sarzi-Puttini P. Etanercept 
plus ciclosporin versus etanercept plus methotrexate for maintaining clinical
control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis. 2011
Apr;70(4):712-4. doi: 10.1136/ard.2010.130864. Epub 2010 Aug 31. PubMed PMID:
20810394.


198: Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD. Treatment of
refractory psoriatic arthritis with infliximab: a 12 month observational study of
16 patients. Ann Rheum Dis. 2004 Feb;63(2):156-61. PubMed PMID: 14722204; PubMed 
Central PMCID: PMC1754892.


199: González-Chavez JR, Berlingeri-Ramos AC, Sánchez Casiano MA. Puerto Rico
psoriasis study group: efficacy and safety of etanercept. J Drugs Dermatol. 2005 
Nov-Dec;4(6):735-9. PubMed PMID: 16302559.


200: Langley GB, Fowles M, Sirett P, Vlieg M, Wigley RD. Double-blind evaluation 
of piroxicam and naproxen following missed dosage in patients with inflammatory
arthritis. N Z Med J. 1985 Jun 26;98(781):490-2. PubMed PMID: 3892383.


201: Veale DJ, Torley HI, Richards IM, O'Dowd A, Fitzsimons C, Belch JJ, Sturrock
RD. A double-blind placebo controlled trial of Efamol Marine on skin and joint
symptoms of psoriatic arthritis. Br J Rheumatol. 1994 Oct;33(10):954-8. PubMed
PMID: 7921757.


202: Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB.
Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin 
Arthritis Rheum. 1995 Jun;24(6):411-21. Review. PubMed PMID: 7667645.


203: Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rødevand E,
Kaufmann C, Mikkelsen K, Kvien TK. Effectiveness and retention rates of
methotrexate in psoriatic arthritis in comparison with methotrexate-treated
patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Apr;69(4):671-6. doi:
10.1136/ard.2009.113308. Epub 2009 Sep 9. PubMed PMID: 19740904.


204: Nestorov I, Zitnik R, DeVries T, Nakanishi AM, Wang A, Banfield C.
Pharmacokinetics of subcutaneously administered etanercept in subjects with
psoriasis. Br J Clin Pharmacol. 2006 Oct;62(4):435-45. PubMed PMID: 16995864;
PubMed Central PMCID: PMC1636685.


205: van Kuijk AW, DeGroot J, Koeman RC, Sakkee N, Baeten DL, Gerlag DM, Tak PP. 
Soluble biomarkers of cartilage and bone metabolism in early proof of concept
trials in psoriatic arthritis: effects of adalimumab versus placebo. PLoS One.
2010 Sep 3;5(9). pii: e12556. doi: 10.1371/journal.pone.0012556. PubMed PMID:
20844595; PubMed Central PMCID: PMC2937309.


206: Singh YN, Verma KK, Kumar A, Malaviya AN. Methotrexate in psoriatic
arthritis. J Assoc Physicians India. 1994 Nov;42(11):860-2. PubMed PMID: 7868484.


207: Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF. Patient-reported
outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol.
2010 Jun;37(6):1221-7. doi: 10.3899/jrheum.091093. Epub 2010 Apr 15. PubMed PMID:
20395648.


208: Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of
1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and
calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens.
2012 Jun;25(6):644-50. doi: 10.1038/ajh.2012.12. Epub 2012 Mar 1. PubMed PMID:
22378036; PubMed Central PMCID: PMC3635528.


209: Mease PJ. Cytokine blockers in psoriatic arthritis. Ann Rheum Dis. 2001
Nov;60 Suppl 3:iii37-40. PubMed PMID: 11890650; PubMed Central PMCID: PMC1766666.


210: Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S,
Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal
antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, 
crossover trial. Lancet. 2009 Feb 21;373(9664):633-40. doi:
10.1016/S0140-6736(09)60140-9. Epub 2009 Feb 11. Erratum in: Lancet. 2009 Apr
18;373(9672):1340. Lancet. 2010 Nov 6;376(9752):1542. PubMed PMID: 19217154.


211: Ward JR. Historical perspective on the use of methotrexate for the treatment
of rheumatoid arthritis. J Rheumatol Suppl. 1985 Dec;12 Suppl 12:3-6. PubMed
PMID: 3913774.


212: Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in
psoriatic arthritis. J Rheumatol. 1992 Nov;19(11):1724-6. PubMed PMID: 1491390.


213: Langley GB, Fowles M, Sheppeard H, Wigley RD. A simple pressure dolorimeter 
for the quantification of joint tenderness in inflammatory arthritis. Rheumatol
Int. 1983;3(3):109-12. PubMed PMID: 6366987.


214: Röhner E, Matziolis G, Perka C, Füchtmeier B, Gaber T, Burmester GR,
Buttgereit F, Hoff P. Inflammatory synovial fluid microenvironment drives primary
human chondrocytes to actively take part in inflammatory joint diseases. Immunol 
Res. 2012 Jun;52(3):169-75. doi: 10.1007/s12026-011-8247-5. PubMed PMID:
21979468.


215: Rudd RE, Blanch DC, Gall V, Chibnik LB, Wright EA, Reichmann W, Liang MH,
Katz JN. A randomized controlled trial of an intervention to reduce low literacy 
barriers in inflammatory arthritis management. Patient Educ Couns. 2009
Jun;75(3):334-9. doi: 10.1016/j.pec.2009.03.001. Epub 2009 Apr 3. PubMed PMID:
19345053; PubMed Central PMCID: PMC2748845.


216: Gottlieb AB, Kircik L, Eisen D, Jackson JM, Boh EE, Strober BE, Frankel E,
Xia HA, Stevens SR. Use of etanercept for psoriatic arthritis in the dermatology 
clinic: the Experience Diagnosing, Understanding Care, and Treatment with
Etanercept (EDUCATE) study. J Dermatolog Treat. 2006;17(6):343-52. PubMed PMID:
17853307.


217: Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH. Risk
factors for radiographic progression in psoriatic arthritis: subanalysis of the
randomized controlled trial ADEPT. Arthritis Res Ther. 2010;12(3):R113. doi:
10.1186/ar3049. Epub 2010 Jun 10. PubMed PMID: 20537151; PubMed Central PMCID:
PMC2911906.


218: Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp
JT, Ory PA, Perdok RJ, Weinberg MA; Adalimumab Effectiveness in Psoriatic
Arthritis Trial Study Group. Adalimumab for the treatment of patients with
moderately to severely active psoriatic arthritis: results of a double-blind,
randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct;52(10):3279-89.
PubMed PMID: 16200601.


219: Battistone MJ, Manaster BJ, Reda DJ, Clegg DO. The prevalence of sacroilitis
in psoriatic arthritis: new perspectives from a large, multicenter cohort. A
Department of Veterans Affairs Cooperative Study. Skeletal Radiol. 1999
Apr;28(4):196-201. PubMed PMID: 10384989.


220: Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ,
Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C; IMPACT 2 Study
Group. Infliximab maintains a high degree of clinical response in patients with
active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2
trial. Ann Rheum Dis. 2007 Apr;66(4):498-505. Epub 2006 Nov 17. PubMed PMID:
17114188; PubMed Central PMCID: PMC1856065.


221: Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M,
Kalden-Nemeth D, Kalden JR, Manger B. Open-label study of infliximab treatment
for psoriatic arthritis: clinical and magnetic resonance imaging measurements of 
reduction of inflammation. Arthritis Rheum. 2002 Oct 15;47(5):506-12. PubMed
PMID: 12382299.


222: Mease PJ, Reich K; Alefacept in Psoriatic Arthritis Study Group. Alefacept
with methotrexate for treatment of psoriatic arthritis: open-label extension of a
randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2009
Mar;60(3):402-11. doi: 10.1016/j.jaad.2008.09.050. Epub 2008 Nov 25. Erratum in: 
J Am Acad Dermatol. 2009 Sep;61(3):507. PubMed PMID: 19028407.


223: de Vlam K, Lories RJ. Efficacy, effectiveness and safety of etanercept in
monotherapy for refractory psoriatic arthritis: a 26-week observational study.
Rheumatology (Oxford). 2006 Mar;45(3):321-4. Epub 2005 Oct 18. PubMed PMID:
16234275.


224: Mease PJ, Gladman DD, Keystone EC; Alefacept in Psoriatic Arthritis Study
Group. Alefacept in combination with methotrexate for the treatment of psoriatic 
arthritis: results of a randomized, double-blind, placebo-controlled study.
Arthritis Rheum. 2006 May;54(5):1638-45. PubMed PMID: 16646026.


225: Eulry F, Mayaudon H, Bauduceau B, Lechevalier D, Crozes P, Magnin J,
Claude-Berthelot C. [Blood prolactin under the effect of protirelin in
spondylarthropathies. Treatment trial of 4 cases of reactive arthritis and 2
cases of psoriatic arthritis with bromocriptine]. Ann Med Interne (Paris).
1996;147(1):15-9. French. PubMed PMID: 8763085.


226: Marzo-Ortega H, McGonagle D, Rhodes LA, Tan AL, Conaghan PG, O'Connor P,
Tanner SF, Fraser A, Veale D, Emery P. Efficacy of infliximab on MRI-determined
bone oedema in psoriatic arthritis. Ann Rheum Dis. 2007 Jun;66(6):778-81. Epub
2006 Dec 21. PubMed PMID: 17185324; PubMed Central PMCID: PMC1954680.


227: Mastroianni A, Minutilli E, Mussi A, Bordignon V, Trento E, D'Agosto G,
Cordiali-Fei P, Berardesca E. Cytokine profiles during infliximab monotherapy in 
psoriatic arthritis. Br J Dermatol. 2005 Sep;153(3):531-6. PubMed PMID: 16120138.


228: Brückle W, Dexel T, Grasedyck K, Schattenkirchner M. Treatment of psoriatic 
arthritis with auranofin and gold sodium thiomalate. Clin Rheumatol. 1994
Jun;13(2):209-16. PubMed PMID: 8088061.


229: Maldyk H, Chwalińska-Sadowska H. [Results of treatment with endoxan of
psoriatic arthropathy and of chronic progressive arthritis]. Reumatologia.
1968;6(2):111-9. Polish. PubMed PMID: 4875487.


230: Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ,
Sasso EH. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight 
week data from the adalimumab effectiveness in psoriatic arthritis trial.
Arthritis Rheum. 2007 Feb;56(2):476-88. PubMed PMID: 17265483.


231: Palmer D, El Miedany Y. EROMIA in inflammatory arthritis: the next step in
standard practice. Br J Nurs. 2010 Jan 14-27;19(1):42-6. PubMed PMID: 20081712.


232: Anandarajah AP, Ory P, Salonen D, Feng C, Wong RL, Ritchlin CT. Effect of
adalimumab on joint disease: features of patients with psoriatic arthritis
detected by magnetic resonance imaging. Ann Rheum Dis. 2010 Jan;69(1):206-9. doi:
10.1136/ard.2008.100149. Epub . PubMed PMID: 19204015.


233: Frediani B, Falsetti P, Baldi F, Acciai C, Filippou G, Marcolongo R. Effects
of 4-year treatment with once-weekly clodronate on prevention of
corticosteroid-induced bone loss and fractures in patients with arthritis:
evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound.
Bone. 2003 Oct;33(4):575-81. PubMed PMID: 14555261.


234: Dalbeth N, Yeoman S, Dockerty JL, Highton J, Robinson E, Tan PL, Herman D,
McQueen FM. A randomised placebo controlled trial of delipidated,
deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis.
Ann Rheum Dis. 2004 Jun;63(6):718-22. PubMed PMID: 15140780; PubMed Central
PMCID: PMC1755035.


235: Willkens RF. Short term efficacy of methotrexate in the treatment of
rheumatoid arthritis. J Rheumatol Suppl. 1985 Dec;12 Suppl 12:21-4. Review.
PubMed PMID: 3913772.


236: Giordano M, Tirri G, Capelli L, Gallo M, Scott GG. [Controlled clinical
research on the use of ibuprofen in rheumatoid arthritis and other rheumatic
diseases]. Minerva Med. 1973 Jun 23;64(47):2483-90. Italian. PubMed PMID:
4579840.


237: Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J
Rheumatol Suppl. 1985 Dec;12 Suppl 12:35-9. Review. PubMed PMID: 3913775.


238: D'Angelo S, Cutro MS, Lubrano E, Leccese P, Mennillo GA, Ferrara N, Olivieri
I. Combination therapy with ciclosporin and etanercept in patients with psoriatic
arthritis. Ann Rheum Dis. 2010 May;69(5):934-5. doi: 10.1136/ard.2009.119446.
Epub 2009 Aug 9. PubMed PMID: 19666936.


239: McKendry RJ, Kraag G, Seigel S, al-Awadhi A. Therapeutic value of colchicine
in the treatment of patients with psoriatic arthritis. Ann Rheum Dis. 1993
Nov;52(11):826-8. PubMed PMID: 8250615; PubMed Central PMCID: PMC1005197.


240: Pchelintseva AO, Korotaeva TV, Godzenko AA, Korsakova IuL, Stanislav ML,
Denisov LN. [Results of leflunomide treatment of psoriatic arthritis]. Ter Arkh. 
2007;79(8):22-8. Russian. PubMed PMID: 17926466.


241: Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich
J, Sasso EH; M02-570 Study Group. Safety and efficacy of adalimumab in treatment 
of patients with psoriatic arthritis who had failed disease modifying
antirheumatic drug therapy. J Rheumatol. 2007 May;34(5):1040-50. Epub 2007 Apr
15. Erratum in: J Rheumatol. 2007 Jun;34(6):1439. PubMed PMID: 17444593.


242: Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of 
NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. 
Clin Exp Rheumatol. 2001;19(1 Suppl 22):S17-20. PubMed PMID: 11296544.


243: Salvarani C, Barozzi L, Boiardi L, Pipitone N, Bajocchi GL, Macchioni PL,
Catanoso M, Pazzola G, Valentino M, De Luca C, Hunder GG. Lumbar interspinous
bursitis in active polymyalgia rheumatica. Clin Exp Rheumatol. 2013
Jul-Aug;31(4):526-31. Epub 2013 May 28. PubMed PMID: 23739147.


244: Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Efalizumab for the treatment
of psoriatic arthritis. J Cutan Med Surg. 2007 Mar-Apr;11(2):57-66. PubMed PMID: 
17374316.


245: Miehlke K, Kafarnik U. [Clinical experiences in the therapy of rheumatoid
arthritis using isophosphamide]. Verh Dtsch Ges Rheumatol. 1972;2:Suppl 2:415-8. 
German. PubMed PMID: 4559449.


246: Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B,
Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E,
Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR,
Smolen JS. Two-year efficacy and safety of infliximab treatment in patients with 
active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic
Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008 May;35(5):869-76. Epub
2008 Mar 15. PubMed PMID: 18381786.


247: Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT, Beutler A,
Guzzo C, Gladman D. Infliximab improves health related quality of life and
physical function in patients with psoriatic arthritis. Ann Rheum Dis. 2006
Apr;65(4):471-7. Epub 2005 Aug 11. PubMed PMID: 16096330; PubMed Central PMCID:
PMC1798094.


248: Bongartz T, Coras B, Vogt T, Schölmerich J, Müller-Ladner U. Treatment of
active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label 
pilot study. Rheumatology (Oxford). 2005 Jan;44(1):126-9. Epub 2004 Oct 12.
PubMed PMID: 15479756.


249: Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB. Effects of tumor
necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a
double-blind, placebo-controlled study. Arthritis Rheum. 2007 Mar;56(3):831-9.
PubMed PMID: 17328057.


250: van Kuijk AW, Gerlag DM, Vos K, Wolbink G, de Groot M, de Rie MA, Zwinderman
AH, Dijkmans BA, Tak PP. A prospective, randomised, placebo-controlled study to
identify biomarkers associated with active treatment in psoriatic arthritis:
effects of adalimumab treatment on synovial tissue. Ann Rheum Dis. 2009
Aug;68(8):1303-9. doi: 10.1136/ard.2008.091389. Epub 2008 Jul 22. PubMed PMID:
18647851; PubMed Central PMCID: PMC2703703.


251: Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and
rifampin in undifferentiated spondyloarthropathy, with special reference to
chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J
Rheumatol. 2004 Oct;31(10):1973-80. PubMed PMID: 15468362.


252: de Seny D, Fillet M, Meuwis MA, Geurts P, Lutteri L, Ribbens C, Bours V,
Wehenkel L, Piette J, Malaise M, Merville MP. Discovery of new rheumatoid
arthritis biomarkers using the surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum. 2005
Dec;52(12):3801-12. PubMed PMID: 16320331.


253: Kanekura T, Kawabata H, Maruyama I, Kanzaki T. Treatment of psoriatic
arthritis with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol.
2004 Feb;50(2):242-6. PubMed PMID: 14726879.


254: Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G,
Cantini F, Salaffi F, Padula A, Lovino C, Dovigo L, Bordin G, Davoli C, Pasero G,
Alberighi OD. A comparison of cyclosporine, sulfasalazine, and symptomatic
therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001
Oct;28(10):2274-82. PubMed PMID: 11669169.


255: Elkayam O, Ophir J, Brener S, Paran D, Wigler I, Efron D, Even-Paz Z, Politi
Y, Yaron M. Immediate and delayed effects of treatment at the Dead Sea in
patients with psoriatic arthritis. Rheumatol Int. 2000;19(3):77-82. PubMed PMID: 
10776684.


256: Burdeĭnyĭ AP. [The efficacy of diclonate P in psoriatic arthritis]. Ter
Arkh. 1994;66(5):75-7. Russian. PubMed PMID: 7940348.


257: Kimball AB, Jackson JM, Sobell JM, Boh EE, Grekin S, Pharmd EB, Woolley JM, 
Xia HA, Chiou CF, Stevens SR. Reductions in healthcare resource utilization in
psoriatic arthritis patients receiving etanercept therapy: results from the
educate trial. J Drugs Dermatol. 2007 Mar;6(3):299-306. PubMed PMID: 17373192.


258: Walker UA, Uhl M, Weiner SM, Warnatz K, Lange-Nolde A, Dertinger H, Peter
HH, Jurenz SA. Analgesic and disease modifying effects of interferential current 
in psoriatic arthritis. Rheumatol Int. 2006 Aug;26(10):904-7. Epub 2006 Jan 24.
PubMed PMID: 16432686.


259: Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH,
Landewé R, Steinfeld SD, Emery P, Dijkmans BA, Veale DJ. A randomised, double
blind, placebo controlled, multicentre trial of combination therapy with
methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann
Rheum Dis. 2005 Jun;64(6):859-64. Epub 2004 Nov 4. PubMed PMID: 15528283; PubMed 
Central PMCID: PMC1755527.


260: Sarzi-Puttini P, Cazzola M, Panni B, Turiel M, Fiorini T, Belai-Beyene N,
Chèrié-Lignièré EL. Long-term safety and efficacy of low-dose cyclosporin A in
severe psoriatic arthritis. Rheumatol Int. 2002 Apr;21(6):234-8. PubMed PMID:
12036210.


261: Leatham PA, Bird HA, Wright V, Fowler PD. The run-in period in trial design:
a comparison of two non-steroidal anti-inflammatory agents in psoriatic
arthropathy. Agents Actions. 1982 Apr;12(1-2):221-4. PubMed PMID: 7044069.


262: Takada K, Danning CL, Kuroiwa T, Schlimgen R, Tassiulas IO, Davis JC Jr,
Yarboro CH, Fleisher TA, Boumpas DT, Illei GG. Lymphocyte depletion with
fludarabine in patients with psoriatic arthritis: clinical and immunological
effects. Ann Rheum Dis. 2003 Nov;62(11):1112-5. PubMed PMID: 14583577; PubMed
Central PMCID: PMC1754350.


263: Salvarani C, Cantini F, Olivieri I, Macchioni P, Padula A, Niccoli L,
Catanoso MG, Scocco GL, Boiardi L. Efficacy of infliximab in resistant psoriatic 
arthritis. Arthritis Rheum. 2003 Aug 15;49(4):541-5. PubMed PMID: 12910561.


264: Cattalini M, Maduskuie V, Fawcett PT, Brescia AM, Rosé CD. Predicting
duration of beneficial effect of joint injection among children with chronic
arthritis by measuring biomarkers concentration in synovial fluid at the time of 
injection. Clin Exp Rheumatol. 2008 Nov-Dec;26(6):1153-60. PubMed PMID: 19210889.


265: Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, Fitzgerald O, Roth
J. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and
psoriatic arthritis. Rheumatology (Oxford). 2003 Nov;42(11):1383-9. Epub 2003 Jun
27. PubMed PMID: 12832707.


266: Fournié B, Crognier L, Arnaud C, Zabraniecki L, Lascaux-Lefebvre V, Marc V, 
Ginesty E, Andrieu V, Dromer C, Fournié A. Proposed classification criteria of
psoriatic arthritis. A preliminary study in 260 patients. Rev Rhum Engl Ed. 1999 
Oct;66(10):446-56. PubMed PMID: 10567972.


267: Iurassich S, Rossi E, Carbone M, Brunese L. [Ultrasound patterns of
rheumatoid and psoriatic arthritis in finger joints]. Radiol Med. 1999
Jul-Aug;98(1-2):15-8. Italian. PubMed PMID: 10566291.


268: Wilke WS, Sexton C, Steck W. Parenteral nitrogen mustard for inflammatory
arthritis. Cleve Clin J Med. 1990 Oct;57(7):643-6. PubMed PMID: 2225450.


269: Kisand K, Bøe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, Ersvaer 
E, Perheentupa J, Erichsen MM, Bratanic N, Meloni A, Cetani F, Perniola R,
Ergun-Longmire B, Maclaren N, Krohn KJ, Pura M, Schalke B, Ströbel P, Leite MI,
Battelino T, Husebye ES, Peterson P, Willcox N, Meager A. Chronic mucocutaneous
candidiasis in APECED or thymoma patients correlates with autoimmunity to
Th17-associated cytokines. J Exp Med. 2010 Feb 15;207(2):299-308. doi:
10.1084/jem.20091669. Epub 2010 Feb 1. PubMed PMID: 20123959; PubMed Central
PMCID: PMC2822605.


270: Mazzotta A, Esposito M, Schipani C, Chimenti S. Long-term experience with
etanercept in psoriatic arthritis patients: a 3-year observational study. J
Dermatolog Treat. 2009;20(6):354-8. doi: 10.3109/09546630902936752. PubMed PMID: 
19954392.


271: Holman AJ, Ng E. Heart rate variability predicts anti-tumor necrosis factor 
therapy response for inflammatory arthritis. Auton Neurosci. 2008 Dec
5;143(1-2):58-67. doi: 10.1016/j.autneu.2008.05.005. Epub 2008 Jul 16. PubMed
PMID: 18632310.


272: Amital H, Barak V, Winkler RE, Rubinow A. Impact of treatment with
infliximab on serum cytokine profile of patients with rheumatoid and psoriatic
arthritis. Ann N Y Acad Sci. 2007 Sep;1110:649-60. PubMed PMID: 17911480.


273: Piazzini M, Fioravanti A, Sabadini L, Vassalli D, Bellisai F, Marcolongo R. 
[Laboratory and instrumental clinical study of 150 patients with psoriatic
arthritis]. Recenti Prog Med. 1995 May;86(5):183-8. Italian. PubMed PMID:
7604173.


274: Rau H, Franke C, Goretzki G, Spitz J. Radiosynoviorthesis in osteoarthritis 
and other disorders with concomitant synovitis in comparison to rheumatoid
arthritis. Cancer Biother Radiopharm. 2005 Jun;20(3):349-55. PubMed PMID:
15989483.


275: van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C,
Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D, Beutler A.
Infliximab inhibits progression of radiographic damage in patients with active
psoriatic arthritis through one year of treatment: Results from the induction and
maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007
Aug;56(8):2698-707. PubMed PMID: 17665424.


276: Husted JA, Gladman DD, Cook RJ, Farewell VT. Responsiveness of health status
instruments to changes in articular status and perceived health in patients with 
psoriatic arthritis. J Rheumatol. 1998 Nov;25(11):2146-55. PubMed PMID: 9818657.


277: Peters MJ, Watt P, Cherry L, Welsh P, Henninger E, Dijkmans BA, McInnes IB, 
Nurmohamed MT, Sattar N. Lack of effect of TNFalpha blockade therapy on
circulating adiponectin levels in patients with autoimmune disease: results from 
two independent prospective studies. Ann Rheum Dis. 2010 Sep;69(9):1687-90. doi: 
10.1136/ard.2009.114207. Epub 2009 Jul 28. PubMed PMID: 19640853.


278: Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, Baker D, Beutler A, Pendley C,
Wagner C, Davis HM, Zhou H. Population pharmacokinetics of golimumab, an
anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with
psoriatic arthritis. J Clin Pharmacol. 2009 Sep;49(9):1056-70. doi:
10.1177/0091270009339192. Epub 2009 Jul 17. PubMed PMID: 19617465.


279: Zhang GL, Huang F, Zhang JL, Li XF. [A clinical study of leflunomide and
methotrexate therapy in psoriatic arthritis]. Zhonghua Nei Ke Za Zhi. 2009
Jul;48(7):570-4. Chinese. PubMed PMID: 19957798.


280: Lassus A. Colloidal silicic acid for the treatment of psoriatic skin
lesions, arthropathy and onychopathy. A pilot study. J Int Med Res. 1997
Jul-Aug;25(4):206-9. PubMed PMID: 9283994.


281: Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, Gottlieb AB.
Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic 
epidermis and downregulation of NF-kappaB in response to treatment with
etanercept. J Invest Dermatol. 2005 Jun;124(6):1275-83. PubMed PMID: 15955104.


282: Fournié B, Margarit-Coll N, Champetier de Ribes TL, Zabraniecki L, Jouan A, 
Vincent V, Chiavassa H, Sans N, Railhac JJ. Extrasynovial ultrasound
abnormalities in the psoriatic finger. Prospective comparative power-doppler
study versus rheumatoid arthritis. Joint Bone Spine. 2006 Oct;73(5):527-31. Epub 
2006 Apr 19. PubMed PMID: 16942893.


283: Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the
treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol. 2000
Nov-Dec;18(6):732-4. PubMed PMID: 11138337.


284: Mattila M, Könönen M, Mattila K. Vertical asymmetry of the mandibular ramus 
and condylar heights measured with a new method from dental panoramic radiographs
in patients with psoriatic arthritis. J Oral Rehabil. 1995 Oct;22(10):741-5.
PubMed PMID: 8606331.


285: Häkkinen A, Häkkinen K, Hannonen P. Effects of strength training on
neuromuscular function and disease activity in patients with recent-onset
inflammatory arthritis. Scand J Rheumatol. 1994;23(5):237-42. PubMed PMID:
7973476.


286: Matucci-Cerinic M, Pignone A, Lotti T, Partsch G, Livi R, Cagnoni M. Gold
salts and somatostatin: a new combined analgesic treatment for psoriatic
arthritis. Drugs Exp Clin Res. 1992;18(2):53-61. PubMed PMID: 1353720.


287: Ambanelli U, Bassi G, Bianchi V, Carcassi U, Caruso I, Colombo B, Goretti P,
Mansoldo G, Marcolongo R, Pasero G, Pellegrini P, Pipitone V, Rubegni M, Todesco 
S, Accardo S, Bedendo A, Cervi G, Chérié-Lignière G, Ciompi M, Fumagalli M,
Giordano N, Lavezzari M, Loizzi P, Manganelli P, Perpignano G, Provvedi D, Rossi 
R. Indoprofen in rheumatic patients with acute episodes: a multicentre trial. J
Int Med Res. 1982;10(6):399-407. PubMed PMID: 6217996.


288: McQueen F, Lassere M, Duer-Jensen A, Wiell C, Conaghan PG, Gandjbakhch F,
Hermann KG, Bird P, Bøyesen P, Peterfy C, Ejbjerg B, Haavardsholm EA, Coates L,
Ostergaard M. Testing an OMERACT MRI scoring system for peripheral psoriatic
arthritis in cross-sectional and longitudinal settings. J Rheumatol. 2009
Aug;36(8):1811-5. doi: 10.3899/jrheum.090351. PubMed PMID: 19671818.


289: Lacaille D, Stein HB, Raboud J, Klinkhoff AV. Longterm therapy of psoriatic 
arthritis: intramuscular gold or methotrexate? J Rheumatol. 2000
Aug;27(8):1922-7. PubMed PMID: 10955334.


290: Kraan MC, van Kuijk AW, Dinant HJ, Goedkoop AY, Smeets TJ, de Rie MA,
Dijkmans BA, Vaishnaw AK, Bos JD, Tak PP. Alefacept treatment in psoriatic
arthritis: reduction of the effector T cell population in peripheral blood and
synovial tissue is associated with improvement of clinical signs of arthritis.
Arthritis Rheum. 2002 Oct;46(10):2776-84. PubMed PMID: 12384938.


291: Sukenik S, Baradin R, Codish S, Neumann L, Flusser D, Abu-Shakra M, Buskila 
D. Balneotherapy at the Dead Sea area for patients with psoriatic arthritis and
concomitant fibromyalgia. Isr Med Assoc J. 2001 Feb;3(2):147-50. PubMed PMID:
11344827.


292: Mahrle G, Schulze HJ, Bräutigam M, Mischer P, Schopf R, Jung EG, Weidinger
G, Färber L. Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic
arthritis. A prospective multicentre study. Br J Dermatol. 1996 Nov;135(5):752-7.
PubMed PMID: 8977676.


293: Leeb BF, Witzmann G, Ogris E, Studnicka-Benke A, Andel I, Schweitzer H,
Smolen JS. Folic acid and cyanocobalamin levels in serum and erythrocytes during 
low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis
patients. Clin Exp Rheumatol. 1995 Jul-Aug;13(4):459-63. PubMed PMID: 7586777.


294: Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT. Longterm 
methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J
Rheumatol. 1995 Feb;22(2):241-5. PubMed PMID: 7738945.


295: Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, Haas-Smith
SA, Ritchlin CT. The effect of etanercept on osteoclast precursor frequency and
enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis.
2008 Mar;67(3):296-301. Epub 2007 Oct 29. PubMed PMID: 17967829.


296: Combe B, Goupille P, Kuntz JL, Tebib J, Lioté F, Bregeon C. Sulphasalazine
in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J
Rheumatol. 1996 Jul;35(7):664-8. PubMed PMID: 8670601.


297: Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI, Bird HA, Nuki G. A
multicentre double-blind comparison of auranofin, intramuscular gold thiomalate
and placebo in patients with psoriatic arthritis. Br J Rheumatol. 1990
Aug;29(4):280-3. PubMed PMID: 2116206.


298: Rigopoulos D, Gregoriou S, Stratigos A, Larios G, Korfitis C, Papaioannou D,
Antoniou C, Ioannides D. Evaluation of the efficacy and safety of infliximab on
psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol.
2008 Aug;159(2):453-6. doi: 10.1111/j.1365-2133.2008.08686.x. Epub 2008 Jun 28.
PubMed PMID: 18565184.


299: Levin RW, Park J, Ostrov B, Reginato A, Baker DG, Bomalaski JS, Borofsky M, 
Gardiner M, Leventhal L, Louthrenoo W, von Feldt J, Kolasinski S, Schumacher HR
Jr. Clinical assessment of the 1987 American College of Rheumatology criteria for
rheumatoid arthritis. Scand J Rheumatol. 1996;25(5):277-81. PubMed PMID: 8921919.


300: Chandran V, Schentag CT, Gladman DD. Sensitivity of the classification of
psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 2007 
Dec 15;57(8):1560-3. PubMed PMID: 18050230.


301: Cañete JD, Pablos JL, Sanmartí R, Mallofré C, Marsal S, Maymó J, Gratacós J,
Mezquita J, Mezquita C, Cid MC. Antiangiogenic effects of anti-tumor necrosis
factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum.
2004 May;50(5):1636-41. PubMed PMID: 15146434.


302: Hammond A, Bryan J, Hardy A. Effects of a modular behavioural arthritis
education programme: a pragmatic parallel-group randomized controlled trial.
Rheumatology (Oxford). 2008 Nov;47(11):1712-8. doi: 10.1093/rheumatology/ken380. 
Epub 2008 Sep 24. PubMed PMID: 18815153.


303: Khan M, Schentag C, Gladman DD. Clinical and radiological changes during
psoriatic arthritis disease progression. J Rheumatol. 2003 May;30(5):1022-6.
PubMed PMID: 12734899.


304: McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, Schlimgen 
R, Lee E, Foster B, Flemming D, Prussin C, Fleisher TA, Boumpas DT. IL-10
improves skin disease and modulates endothelial activation and leukocyte effector
function in patients with psoriatic arthritis. J Immunol. 2001 Oct
1;167(7):4075-82. PubMed PMID: 11564829.


305: Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in 
psoriatic arthritis: a clinic experience. J Rheumatol. 1998 Oct;25(10):1957-61.
PubMed PMID: 9779850.


306: Tsubota H, Kataura A, Kukuminato Y, Hamamoto M, Ohguro S, Shido F, Takezawa 
H, Shintani T, Hirao M, Saitoh H. [Efficacy of tonsillectomy for improving skin
lesions of Pustulosis palmaris et plantaris--evaluation of 289 cases at the
Department of Otolaryngology of Sapporo Medical University]. Nihon Jibiinkoka
Gakkai Kaiho. 1994 Sep;97(9):1621-30. Japanese. PubMed PMID: 7965376.


307: Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab
improves joint-related and skin-related functional impairment in patients with
psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in
Psoriatic Arthritis Trial. Ann Rheum Dis. 2007 Feb;66(2):163-8. Epub 2006 Oct 17.
PubMed PMID: 17046964; PubMed Central PMCID: PMC1798491.


308: Rovensky J, Raffayova H, Imrich R, Radikova Z, Penesova A, Macho L, Lukac J,
Matucci-Cerinic M, Vigas M. Prolactin and growth hormone responses to
hypoglycemia in patients with systemic sclerosis and psoriatic arthritis. Ann N Y
Acad Sci. 2006 Jun;1069:145-8. PubMed PMID: 16855141.


309: Raffayová H, Rovenský J, Mális F. Treatment with cyclosporin in patients
with psoriatic arthritis: results of clinical assessment. Int J Clin Pharmacol
Res. 2000;20(1-2):1-11. Review. PubMed PMID: 11146896.


310: Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, McCune
WJ. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo
controlled trial. J Rheumatol. 1995 May;22(5):894-8. PubMed PMID: 8587078.


311: Ipatova OM, Nasonov EL, Korotaeva TV, Firsov NN, Ivkina OA, Torkhovskaia TI,
Archakov AI. [Hemorheological and clinical efficiency of a new phospholipid
hepatoprotective drug Phosphogliv in patients with psoriatic arthritis]. Biomed
Khim. 2003 Sep-Oct;49(5):484-90. Russian. PubMed PMID: 16119102.


312: Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G, Salonen D. Radiological
assessment in psoriatic arthritis. Br J Rheumatol. 1998 Jul;37(7):760-5. PubMed
PMID: 9714353.


313: Busson M. A long-term study of flurbiprofen in rheumatological disorders:
III. Other articular conditions. J Int Med Res. 1986;14(1):13-8. PubMed PMID:
3514311.


314: Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative
complications in patients with rheumatoid arthritis undergoing elective
orthopaedic surgery. Ann Rheum Dis. 2001 Mar;60(3):214-7. PubMed PMID: 11171680; 
PubMed Central PMCID: PMC1753573.


315: Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR. A comparison of
the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in
treating the signs and symptoms of psoriatic arthritis. Semin Arthritis Rheum.
2007 Dec;37(3):164-73. Epub 2007 Jun 14. PubMed PMID: 17570469.


316: Groff GD, Shenberger KN, Wilke WS, Taylor TH. Low dose oral methotrexate in 
rheumatoid arthritis: an uncontrolled trial and review of the literature. Semin
Arthritis Rheum. 1983 May;12(4):333-47. Review. PubMed PMID: 6348949.


317: Ricci M, De Marco G, Desiati F, Mazzocchi D, Rotunno L, Battafarano N,
Marchesoni A. [Long-term survival of methotrexate in psoriatic arthritis].
Reumatismo. 2009 Apr-Jun;61(2):125-31. Italian. PubMed PMID: 19633799.


318: Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, Zhou B, Dooley LT,
Beutler A, Guzzo C, Krueger GG. Effect of infliximab therapy on employment, time 
lost from work, and productivity in patients with psoriatic arthritis. J
Rheumatol. 2006 Nov;33(11):2254-9. Epub 2006 Sep 1. PubMed PMID: 16960923.


319: Kanekura T, Hiraishi K, Kawahara K, Maruyama I, Kanzaki T. Granulocyte and
monocyte adsorption apheresis (GCAP) for refractory skin diseases caused by
activated neutrophils and psoriatic arthritis: evidence that GCAP removes
Mac-1-expressing neutrophils. Ther Apher Dial. 2006 Jun;10(3):247-56. PubMed
PMID: 16817789.


320: Madland TM, Björkkjaer T, Brunborg LA, Fröyland L, Berstad A, Brun JG.
Subjective improvement in patients with psoriatic arthritis after short-term oral
treatment with seal oil. A pilot study with double blind comparison to soy oil. J
Rheumatol. 2006 Feb;33(2):307-10. PubMed PMID: 16465662.


321: Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, Keenan
G, Burmester G, Furst DE, Weisman MH, Kalden JR, Smolen J, van der Heijde D. The 
Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results
of radiographic analyses after 1 year. Ann Rheum Dis. 2006 Aug;65(8):1038-43.
Epub 2006 Jan 26. PubMed PMID: 16439444; PubMed Central PMCID: PMC1798249.


322: Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML,
Bluestone JA, Clark MR. Modified anti-CD3 therapy in psoriatic arthritis: a phase
I/II clinical trial. J Rheumatol. 2002 Sep;29(9):1907-13. PubMed PMID: 12233885.


323: Conti F, Ceccarelli F, Priori R, Iagnocco A, Signore A, Valesini G.
Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic
arthritis with monoarthritis resistant to local glucocorticoids. Clinical
efficacy extended to patients on systemic anti-tumour necrosis factor alpha. Ann 
Rheum Dis. 2008 Dec;67(12):1787-90. doi: 10.1136/ard.2008.091900. PubMed PMID:
19005158.


324: Gratacós J, Casado E, Real J, Torre-Alonso JC. Prediction of major clinical 
response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.
Ann Rheum Dis. 2007 Apr;66(4):493-7. Epub 2006 Dec 19. PubMed PMID: 17179176;
PubMed Central PMCID: PMC1856049.


325: Ghanem N, Uhl M, Pache G, Bley T, Walker UA, Langer M. MRI in psoriatic
arthritis with hand and foot involvement. Rheumatol Int. 2007 Feb;27(4):387-93.
Epub 2006 Oct 7. PubMed PMID: 17028861.


326: Cauza E, Hanusch-Enserer U, Frischmuth K, Fabian B, Dunky A, Kostner K.
Short-term infliximab therapy improves symptoms of psoriatic arthritis and
decreases concentrations of cartilage oligomeric matrix protein. J Clin Pharm
Ther. 2006 Apr;31(2):149-52. PubMed PMID: 16635048.


327: Covelli M, Scioscia C, Iannone F, Lapadula G. Repeated infusions of low-dose
infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not
maintained after discontinuation of infliximab. Clin Exp Rheumatol. 2005
Mar-Apr;23(2):145-51. PubMed PMID: 15895882.


328: Kumar N, Kay LJ, Walker DJ. The treatment of enthesitis in psoriatic
arthritis. J Rheumatol. 2004 Nov;31(11):2311-2; author reply 2312-3. PubMed PMID:
15536671.


329: Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ,
Whitmore JB. Pneumococcal vaccine response in psoriatic arthritis patients during
treatment with etanercept. J Rheumatol. 2004 Jul;31(7):1356-61. PubMed PMID:
15229957.


330: Fournié B, Boutes A, Dromer C, Sixou L, Le Guennec P, Granel J, Railhac JJ. 
Prospective study of anterior chest wall involvement in ankylosing spondylitis
and psoriatic arthritis. Rev Rhum Engl Ed. 1997 Jan;64(1):22-5. PubMed PMID:
9051856.


331: Rappaport BZ, Fausti SA, Schechter MA, Frey RH. A prospective study of
high-frequency auditory function in patients receiving oral neomycin. Scand
Audiol. 1986;15(2):67-71. PubMed PMID: 3092343.


332: Roux H, Maestracci D, Recordier AM. [Letter: D penicillamine and psoriatic
polyarthritis]. Nouv Presse Med. 1975 Apr 12;4(15):1133. French. PubMed PMID:
1094415.


333: Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR, Smith
CD. The effect of low dose methotrexate on bone density. J Rheumatol. 2001
Nov;28(11):2395-9. PubMed PMID: 11708409.


334: Scarpa R, Peluso R, Atteno M, Manguso F, Spanò A, Iervolino S, Di Minno MN, 
Costa L, Del Puente A. The effectiveness of a traditional therapeutical approach 
in early psoriatic arthritis: results of a pilot randomised 6-month trial with
methotrexate. Clin Rheumatol. 2008 Jul;27(7):823-6. Epub 2007 Nov 21. PubMed
PMID: 18030515.


335: Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E,
Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR Jr, Silverman SL,
Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ,
Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in
the treatment of psoriatic arthritis. A Department of Veterans Affairs
Cooperative Study. Arthritis Rheum. 1996 Dec;39(12):2013-20. PubMed PMID:
8961906.


336: Heald AE, Fudman EJ, Anklesaria P, Mease PJ; 13G01 Study Team. Single-joint 
outcome measures: preliminary validation of patient-reported outcomes and
physical examination. J Rheumatol. 2010 May;37(5):1042-8. doi:
10.3899/jrheum.090827. Epub 2010 Mar 15. PubMed PMID: 20231202.


337: Cantini F, Niccoli L, Nannini C, Cassarà E, Pasquetti P, Olivieri I,
Salvarani C. Frequency and duration of clinical remission in patients with
peripheral psoriatic arthritis requiring second-line drugs. Rheumatology
(Oxford). 2008 Jun;47(6):872-6. doi: 10.1093/rheumatology/ken059. Epub 2008 Apr
9. PubMed PMID: 18400836.


338: Pontikaki I, Gerloni V, Gattinara M, Luriati A, Salmaso A, De Marco G,
Teruzzi B, Valcamonica E, Fantini F. [Side effects of anti-TNFalpha therapy in
juvenile idiopathic arthritis]. Reumatismo. 2006 Jan-Mar;58(1):31-8. Italian.
PubMed PMID: 16639486.


339: Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X,
Claudepierre P. Infliximab to etanercept switch in patients with
spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol.
2005 Nov;32(11):2183-5. PubMed PMID: 16265699.


340: Simonova OV, Nemtsov BF. [Psoriatic arthritis: combined treatment with
prospidin and methotrexate]. Ter Arkh. 2005;77(8):60-4. Russian. PubMed PMID:
16206608.


341: Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A.
Comparison of cyclosporin A and methotrexate in the treatment of psoriatic
arthritis: a one-year prospective study. Clin Exp Rheumatol. 1995
Sep-Oct;13(5):589-93. PubMed PMID: 8575136.


342: Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA.
Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol. 1993
Oct;32(10):923-5. PubMed PMID: 8104656.


343: Espinoza LR, Zakraoui L, Espinoza CG, Gutiérrez F, Jara LJ, Silveira LH,
Cuéllar ML, Martínez-Osuna P. Psoriatic arthritis: clinical response and side
effects to methotrexate therapy. J Rheumatol. 1992 Jun;19(6):872-7. PubMed PMID: 
1404123.


344: Könönen M, Kilpinen E. Comparison of three radiographic methods in screening
of temporomandibular joint involvement in patients with psoriatic arthritis. Acta
Odontol Scand. 1990 Aug;48(4):271-7. PubMed PMID: 2220335.


345: Ujfalussy I, Koó E, Seszták M. Termination of disease modifying
antirheumatic drugs in psoriatic arthritis. J Rheumatol. 2001 Mar;28(3):682-3.
PubMed PMID: 11296986.


346: Spadaro A, Taccari E, Sensi F, Riccieri V, Sili Scavalli A, Zoppini A.
Soluble interleukin-2 receptor and interleukin-6 levels: evaluation during
cyclosporin A and methotrexate treatment in psoriatic arthritis. Clin Rheumatol. 
1998;17(1):83-5. PubMed PMID: 9586691.


347: Burdeĭnyĭ AP, Agababova ER, Korotaeva TV, Kharamil'o LF. [The comparative
efficacy of slow-acting (basic) preparations in psoriatic arthritis]. Ter Arkh.
1992;64(5):54-9. Russian. PubMed PMID: 1360714.


348: Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G,
Karvounaris S, Bizaki A, Kritikos H, Boumpas DT. Modest but sustained increase of
serum high density lipoprotein cholesterol levels in patients with inflammatory
arthritides treated with infliximab. J Rheumatol. 2006 Dec;33(12):2440-6. Epub
2006 Oct 1. PubMed PMID: 17014005.


349: Jahangier ZN, Jacobs JW, Kraan MC, Wenting MJ, Smeets TJ, Bijlsma JW,
Lafeber FP, Tak PP. Pretreatment macrophage infiltration of the synovium predicts
the clinical effect of both radiation synovectomy and intra-articular
glucocorticoids. Ann Rheum Dis. 2006 Oct;65(10):1286-92. Epub 2006 Apr 20. PubMed
PMID: 16627543; PubMed Central PMCID: PMC1798328.


350: Frey FJ. [Cyclosporin in autoimmune diseases]. Schweiz Med Wochenschr. 1990 
May 26;120(21):772-86. Review. German. PubMed PMID: 2190313.


351: Ritchlin C. Efficacy and safety of infliximab for the treatment of psoriatic
arthritis. Nat Clin Pract Rheumatol. 2006 Jun;2(6):300-1. PubMed PMID: 16932707.


352: Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe,
resistant psoriatic arthritis: continued efficacy and changing patterns of use
after two years. Clin Exp Rheumatol. 2002 Jan-Feb;20(1):115. PubMed PMID:
11892697.


353: Spadaro A, Taccari E, Mohtadi B, Riccieri V, Sensi F, Zoppini A. Life-table 
analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other
disease-modifying antirheumatic drugs. Clin Exp Rheumatol. 1997
Nov-Dec;15(6):609-14. PubMed PMID: 9444416.


354: Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life-table analysis of
etanercept with or without methotrexate in patients with psoriatic arthritis. Ann
Rheum Dis. 2008 Nov;67(11):1650-1. doi: 10.1136/ard.2007.085951. PubMed PMID:
18854519.


355: Rinaldi F, Provenzano G, Termini A, Spinello M, La Seta F. Long term
infliximab treatment for severe psoriatic arthritis: evidence of sustained
clinical and radiographic response. Ann Rheum Dis. 2005 Sep;64(9):1375-6. PubMed 
PMID: 16100346; PubMed Central PMCID: PMC1755641.


356: Navarro-Blasco FJ, Sempere JM. Modification of the inflammatory activity of 
psoriatic arthritis in patients treated with extract of Polipodium leucotomos
(Anapsos). Br J Rheumatol. 1998 Aug;37(8):912. PubMed PMID: 9734685.


357: Mazzanti G, Coloni L, De Sabbata G, Paladini G. Methotrexate and cyclosporin
combined therapy in severe psoriatic arthritis. A pilot study. Acta Derm Venereol
Suppl (Stockh). 1994;186:116-7. PubMed PMID: 8073808.


358: Peeters AJ, Dijkmans BA, van der Schroeff JG. Fumaric acid therapy for
psoriatic arthritis. A randomized, double-blind, placebo-controlled study. Br J
Rheumatol. 1992 Jul;31(7):502-4. PubMed PMID: 1628175.


359: Yy DT, Clements PJ, Peter JB, Levy J, Paulus HE, Barnett EV. Lymphocyte
characteristics in rheumatic patients and the effect of azathioprine therapy.
Arthritis Rheum. 1974 Jan-Feb;17(1):37-45. PubMed PMID: 4589815.


360: Sellam J, Allanore Y, Batteux F, Deslandre CJ, Weill B, Kahan A.
Autoantibody induction in patients with refractory spondyloarthropathy treated
with infliximab and methotrexate. Joint Bone Spine. 2005 Jan;72(1):48-52. PubMed 
PMID: 15681248.


361: Sigidin IaA, Murav'ev IuV. [Experience with using a new antirheumatic drug
flugalin]. Ter Arkh. 1985;57(8):57-9. Russian. PubMed PMID: 3906996.


362: Grassi W, Filippucci E, Farina A, Cervini C. Sonographic imaging of the
distal phalanx. Semin Arthritis Rheum. 2000 Jun;29(6):379-84. PubMed PMID:
10924024.


363: De Souza A, Strober BE, Merola JF, Oliver S, Franks AG Jr. Apremilast for
discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot 
study. J Drugs Dermatol. 2012 Oct;11(10):1224-6. PubMed PMID: 23134988.


364: Bridgman JF, Bruckner F, Bleehen NM. Radioactive yttrium in the treatment of
rheumatoid knee effusions. Preliminary evaluation. Ann Rheum Dis. 1971
Mar;30(2):180-2. PubMed PMID: 5569439; PubMed Central PMCID: PMC1005747.


365: Willkens RF. Reappraisal of the use of methotrexate in rheumatic disease. Am
J Med. 1983 Oct 31;75(4B):19-25. Review. PubMed PMID: 6356904.


366: Perkins ES, MacFaul PA. Indomethacin in the treatment of uveitis. A
double-blind trial. Trans Ophthalmol Soc U K. 1965;85:53-8. PubMed PMID: 5335698.


367: Kuzell WC, Seebach LM, Glover RP, Jackman AE. Treatment of gout with
allopurinol and sulphinpyrazone in combination and with allopurinol alone. Ann
Rheum Dis. 1966 Nov;25(6 Suppl):634-42. doi: 10.1136/ard.25.Suppl_6.634. PubMed
PMID: 5335061; PubMed Central PMCID: PMC2453410.


368: Holzmann H, Thiers G, Altmeyer P, Maul FD, Hör G. [Therapy of psoriatic
osteoarthropathy with EHDP]. Hautarzt. 1985 Jun;36(6):326-30. German. PubMed
PMID: 3926720.


369: Chou CT. The clinical application of etanercept in Chinese patients with
rheumatic diseases. Mod Rheumatol. 2006;16(4):206-13. PubMed PMID: 16906369.


370: Hoffmann M, Kumar G, Schafer P, Cedzik D, Capone L, Fong KL, Gu Z, Heller D,
Feng H, Surapaneni S, Laskin O, Wu A. Disposition, metabolism and mass balance of
[(14)C]apremilast following oral administration. Xenobiotica. 2011
Dec;41(12):1063-75. doi: 10.3109/00498254.2011.604745. Epub 2011 Aug 23. PubMed
PMID: 21859393; PubMed Central PMCID: PMC3231940.


371: Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of
leflunomide in active ankylosing spondylitis. Ann Rheum Dis. 2005
Jan;64(1):124-6. PubMed PMID: 15608310; PubMed Central PMCID: PMC1755172.


372: Fiocco U, Ferro F, Vezzù M, Cozzi L, Checchetto C, Sfriso P, Botsios C,
Ciprian L, Armellin G, Nardacchione R, Piccoli A, Todesco S, Rubaltelli L.
Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler 
ultrasound assessment of the response to etanercept. Ann Rheum Dis. 2005
Jun;64(6):899-905. Epub 2004 Nov 26. PubMed PMID: 15567814; PubMed Central PMCID:
PMC1755540.


373: Somerville MF, Scott DG. Neoral--new cyclosporin for old? Br J Rheumatol.
1997 Oct;36(10):1113-5. PubMed PMID: 9374930.


374: Ferraccioli G, Guerra P, Rizzi V, Bartoli E. Cyclosporin A increases
somatomedin C insulin-like growth factor I levels in chronic rheumatic diseases. 
J Rheumatol. 1995 Jun;22(6):1060-4. PubMed PMID: 7674231.


375: Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys 
E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B, et al. Sulfasalazine in the
treatment of spondylarthropathy. A randomized, multicenter, double-blind,
placebo-controlled study. Arthritis Rheum. 1995 May;38(5):618-27. PubMed PMID:
7748217.


376: van der Bijl AE, Emmer BJ, Breedveld FC, Middelkoop HA, Jurgens CK, van
Buchem MA, Huizinga TW, van der Grond J. Advanced magnetic resonance imaging of
the brain in patients treated with TNF-alpha blocking agents. Clin Exp Rheumatol.
2007 Mar-Apr;25(2):301-4. PubMed PMID: 17543158.


377: Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for
the treatment of axial and peripheral articular manifestations of the
seronegative spondylarthropathies: a Department of Veterans Affairs cooperative
study. Arthritis Rheum. 1999 Nov;42(11):2325-9. PubMed PMID: 10555027.


378: Navarro-Sarabia F, Fernández-Sueiro JL, Torre-Alonso JC, Gratacos J, Queiro 
R, Gonzalez C, Loza E, Linares L, Zarco P, Juanola X, Román-Ivorra J, Martín-Mola
E, Sanmartí R, Mulero J, Diaz G, Armendáriz Y, Collantes E. High-dose etanercept 
in ankylosing spondylitis: results of a 12-week randomized, double blind,
controlled multicentre study (LOADET study). Rheumatology (Oxford). 2011
Oct;50(10):1828-37. doi: 10.1093/rheumatology/ker083. Epub 2011 Jun 23. PubMed
PMID: 21700683.


379: Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro
M, Portales RG, González-Mari MV, Laffón A, García-Vicuña R. Treatment of
rheumatic inflammatory disease in 25 patients with secondary amyloidosis using
tumor necrosis factor alpha antagonists. Am J Med. 2005 May;118(5):552-6. Erratum
in: Am J Med. 2006 Feb;119(2):191. Garcia-Vicuna, Rosa [corrected to Portales,
Rosa García ]. PubMed PMID: 15866260.


380: Bunchuk NV, Rumiantseva OA, Loginova EIu, Bochkova AG, Storozhakov GI,
Ettinger OA, Kosiura SD, Kamalova RG, Valishina LM. [The efficacy and safety of
infliximab in patients with ankylosing spondylitis: results of an open-labeled
multicenter study]. Ter Arkh. 2010;82(10):41-6. Russian. PubMed PMID: 21341463.


381: Sidiropoulos P, Kritikos HD, Siakka P, Mamoulaki M, Kouroumali H, Voudouris 
K, Boumpas DT. Low dose of infliximab is inadequate in most patients with
spondylarthropathies. Clin Exp Rheumatol. 2005 Jul-Aug;23(4):513-6. PubMed PMID: 
16095121.


382: Baeten D, Van den Bosch F, Elewaut D, Stuer A, Veys EM, De Keyser F. Needle 
arthroscopy of the knee with synovial biopsy sampling: technical experience in
150 patients. Clin Rheumatol. 1999;18(6):434-41. PubMed PMID: 10638766.


383: Mandel SJ, Brent GA, Weinblatt M, Larsen PR. Prospective studies of thyroid 
function in patients receiving gold therapy. Thyroid. 1995 Apr;5(2):113-6. PubMed
PMID: 7647570.


384: Lukoschek M, Simank HG, Brocai DR. [Cementless hip prosthesis in
inflammatory rheumatic diseases]. Orthopade. 1998 Jun;27(6):392-5. German. PubMed
PMID: 9697147.


385: Hanta I, Ozbek S, Kuleci S, Sert M, Kocabas A. Isoniazid intervention for
latent tuberculosis among 86 patients with rheumatologic disease administered
with anti-TNFalpha. Clin Rheumatol. 2007 Nov;26(11):1867-70. Epub 2007 Feb 27.
PubMed PMID: 17332973.


386: Healy PJ, Helliwell PS. Measuring dactylitis in clinical trials: which is
the best instrument to use? J Rheumatol. 2007 Jun;34(6):1302-6. Epub 2007 Feb 15.
PubMed PMID: 17309128.


387: Möller K, Sollerman C, Geijer M, Kopylov P, Tägil M. Avanta versus Swanson
silicone implants in the MCP joint--a prospective, randomized comparison of 30
patients followed for 2 years. J Hand Surg Br. 2005 Feb;30(1):8-13. PubMed PMID: 
15620485.


388: Fiocco U, Cozzi L, Rigon C, Chieco-Bianchi F, Baldovin M, Cassisi GA, Gallo 
C, Doria A, Favaro MA, Piccoli A, de Candia A, Rubaltelli L, Todesco S.
Arthroscopic synovectomy in rheumatoid and psoriatic knee joint synovitis:
long-term outcome. Br J Rheumatol. 1996 May;35(5):463-70. PubMed PMID: 8646438.


389: de Almeida FA, Albanesi Filho FM, de Albuquerque EM, Magalhaes EC, de
Menezes ME. [Echocardiography in the evaluation of cardiac involvement in
seronegative spondylo-arthropathies]. Medicina (B Aires). 1995;55(3):231-6.
Spanish. PubMed PMID: 8544721.


390: O'Duffy EK, Oliver FJ, Chatters SJ, Walker H, Lloyd DC, Edwards JC, Ell PJ. 
Chromosomal analysis of peripheral lymphocytes of patients before and after
radiation synovectomy with samarium-153 particulate hydroxyapatite. Rheumatology 
(Oxford). 1999 Apr;38(4):316-20. PubMed PMID: 10378707.


391: Gaál J, Lakos G, Szodoray P, Kiss J, Horváth I, Horkay E, Nagy G, Szegedi A.
Immunological and clinical effects of alphacalcidol in patients with psoriatic
arthropathy: results of an open, follow-up pilot study. Acta Derm Venereol.
2009;89(2):140-4. doi: 10.2340/00015555-0555. PubMed PMID: 19325997.


392: Gladman DD, Inman RD, Cook RJ, van der Heijde D, Landewé RB, Braun J, Davis 
JC, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'Shea
FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ,
Maksymowych WP. International spondyloarthritis interobserver reliability
exercise--the INSPIRE study: I. Assessment of spinal measures. J Rheumatol. 2007 
Aug;34(8):1733-9. Epub 2007 Jul 1. PubMed PMID: 17611985.


393: Wei JC, Chan TW, Lin HS, Huang F, Chou CT. Thalidomide for severe refractory
ankylosing spondylitis: a 6-month open-label trial. J Rheumatol. 2003
Dec;30(12):2627-31. PubMed PMID: 14719205.


394: Kankonkar SR, Raikar SC, Joshi SV, Tijoriwala SJ. Association of HLA B27
antigen in Indian patients of ankylosing spondylitis and other autoimmune
diseases. J Assoc Physicians India. 1998 Apr;46(4):345-50. PubMed PMID: 11273314.


395: Arthur V, Jubb R, Homer D. Self-injection of gold and methotrexate. J
Rheumatol. 2001 Jan;28(1):212. PubMed PMID: 11196528.


396: Saviola G, Abdi Ali L, Shams Eddin S, Coppini A, Cavalieri F, Campostrini L,
Sacco S, Bucci M, Cirino G, Rossini M. Compared clinical efficacy and bone
metabolic effects of low-dose deflazacort and methyl prednisolone in male
inflammatory arthropathies: a 12-month open randomized pilot study. Rheumatology 
(Oxford). 2007 Jun;46(6):994-8. Epub 2007 Mar 23. PubMed PMID: 17384176.


397: Stenström CH, Arge B, Sundbom A. Home exercise and compliance in
inflammatory rheumatic diseases--a prospective clinical trial. J Rheumatol. 1997 
Mar;24(3):470-6. PubMed PMID: 9058651.


398: Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats
A, Dijkmans B, Olivieri I, Pasero G, et al. The European Spondylarthropathy Study
Group preliminary criteria for the classification of spondylarthropathy.
Arthritis Rheum. 1991 Oct;34(10):1218-27. PubMed PMID: 1930310.


399: Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis
after low-dose methotrexate therapy in primary biliary cirrhosis.
Gastroenterology. 1994 Jul;107(1):266-70. PubMed PMID: 8020670.


400: Zhou H, Parks V, Patat A, Le Coz F, Simcoe D, Korth-Bradley J. Absence of a 
clinically relevant interaction between etanercept and digoxin. J Clin Pharmacol.
2004 Nov;44(11):1244-51. PubMed PMID: 15496642.


401: Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, Landewé
RB, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'Shea
FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, van
der Heijde D. International spondyloarthritis interobserver reliability
exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and
dactylitis. J Rheumatol. 2007 Aug;34(8):1740-5. PubMed PMID: 17659754.


402: Le Quintrec JL, Menkès CJ, Amor B. [Severe psoriatic rheumatism. Treatment
with azathioprine. Report of 11 cases]. Rev Rhum Mal Osteoartic. 1990
Nov;57(11):815-9. French. PubMed PMID: 2291073.


403: Rowin J. Etanercept treatment in myasthenia gravis. Ann N Y Acad Sci.
2008;1132:300-4. doi: 10.1196/annals.1405.028. PubMed PMID: 18567881.


404: Tubach F, Ravaud P, Salmon-Céron D, Petitpain N, Brocq O, Grados F,
Guillaume JC, Leport J, Roudaut A, Solau-Gervais E, Lemann M, Mariette X,
Lortholary O; Recherce Axée sur la Tolérance des Biothérapies Group. Emergence of
Legionella pneumophila pneumonia in patients receiving tumor necrosis
factor-alpha antagonists. Clin Infect Dis. 2006 Nov 15;43(10):e95-100. Epub 2006 
Oct 16. PubMed PMID: 17051484.


405: Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated 
with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford). 2004
May;43(5):658-61. Epub 2004 Feb 24. PubMed PMID: 14983108.

